WMJ 05 2013

COUNTRY
• 64rd
WMA General Assembly and 195th
/196th
Council
Sessions
• Declaration of Helsinki
vol. 59
MedicalWorld
Journal
Official Journal of the World Medical Association, INC
G20438
Nr. 5, October 2013
Cover picture from Norway
Editor in Chief
Dr. Pēteris Apinis
Latvian Medical Association
Skolas iela 3, Riga, Latvia
Phone +371 67 220 661
peteris@arstubiedriba.lv
editorin-chief@wma.net
Co-Editor
Prof. Dr. med. Elmar Doppelfeld
Deutscher Ärzte-Verlag
Dieselstr. 2, D-50859 Köln, Germany
Assistant Editor
Velta Pozņaka
wmj-editor@wma.net
Journal design and
cover design by
Pēteris Gricenko
Layout and Artwork
The Latvian Medical Publisher
“Medicīnas apgāds”,
President Dr. Maija Šetlere,
Katrīnas iela 2, Riga, Latvia
Cover painting:
The painters name is: Karl Aspelin (1857–1932)
The name of the painting is: Läkarebesöket,
1880-talet (the doctor appointment, from the
1880th
). Oil on canvas.
Publisher
The World Medical Association, Inc. BP 63
01212 Ferney-Voltaire Cedex, France
Publishing House
Publishing House
Deutscher-Ärzte Verlag GmbH,
Dieselstr. 2, P.O.Box 40 02 65
50832 Cologne/Germany
Phone (0 22 34) 70 11-0
Fax (0 22 34) 70 11-2 55
Producer
Alexander Krauth
Business Managers J. Führer, N. Froitzheim
50859 Köln, Dieselstr. 2, Germany
IBAN: DE83370100500019250506
BIC: PBNKDEFF
Bank: Deutsche Apotheker- und Ärztebank,
IBAN: DE28300606010101107410
BIC: DAAEDEDD
50670 Cologne, No. 01 011 07410
Advertising rates available on request
The magazine is published bi-mounthly.
Subscriptions will be accepted by
Deutscher Ärzte-Verlag or
the World Medical Association
Subscription fee € 22,80 per annum (incl. 7%
MwSt.). For members of the World Medical
Association and for Associate members the
subscription fee is settled by the membership
or associate payment. Details of Associate
Membership may be found at the World
Medical Association website
www.wma.net
Printed by
Deutscher Ärzte-Verlag
Cologne, Germany
ISSN: 0049-8122
Dr. Margaret MUNGHERERA
WMA President
Uganda Medical Association
Plot 8, 41-43 circular rd., P.O. Box
29874
Kampala
Uganda
Dr. Leonid EIDELMAN
WMA Chairperson of the Finance
and Planning Committee
Israel Medical Asociation
2 Twin Towers, 35 Jabotinsky St.
P.O.Box 3566, Ramat-Gan 52136
Israel
Dr. Masami ISHII
WMA Vice-Chairman of Council
Japan Medical Assn
2-28-16 Honkomagome
Bunkyo-ku
Tokyo 113-8621
Japan
Dr. Cecil B. WILSON
WMA Immediate Past-President
American Medical Association
515 North State Street
60654 Chicago, Illinois
United States
Sir Michael MARMOT
WMA Chairperson of the Socio-
Medical-Affairs Committee
British Medical Association
BMA House,Tavistock Square
London WC1H 9JP
United Kingdom
Dr. Guy DUMONT
WMA Chairperson of the Associate
Members
14 rue des Tiennes
1380 Lasne
Belgium
Dr. Xavier DEAU
WMA President-Elect
Conseil National de l’Ordre des
Médecins (CNOM)
180, Blvd. Haussmann
75389 Paris Cedex 08
France
Dr. Heikki PÄLVE
WMA Chairperson of the Medical
Ethics Committee
Finnish Medical Association
P.O. Box 49
00501 Helsinki
Finland
Dr.Frank Ulrich MONTGOMERY
WMA Treasurer
Herbert-Lewin-Platz 1
(Wegelystrasse)
10623 Berlin
Germany
Dr. Mukesh HAIKERWAL
WMA Chairperson of Council
58 Victoria Street
Williamstown, VIC 3016
Australia
Dr. Otmar KLOIBER
WMA Secretary General
13 chemin du Levant
01212 Ferney-Voltaire
France
World Medical Association Officers, Chairpersons and Officials
Official Journal of the World Medical Association
Opinions expressed in this journal – especially those in authored contributions – do not necessarily reflect WMA policy or positions
www.wma.net
161
Members of the World Medical General
Assembly, colleagues, guests and our hosts
the Brazilian Medical Association:
Since my inauguration last year in Bang-
kok, it has been my privilege to represent
the World Medical Association (WMA)
around the world.
I’ve traveled to at a total of five continents,
twelve countries and attended twenty-nine
meetings and conferences.
I’ve also reported on my travels and the var-
ied and important activities of this organi-
zation on the WMA website through the
President’s Blog.
The message I have carried may be summed
up as follows:
1. The moral imperative of ethics in medicine.
2. The challenge of noncommunicable dis-
ease and the social determinants of health.
3. The threat of climate change.
First, the moral imperative of ethics in
medicine
As you all are aware, the WMA has been
very involved in the process of bringing the
Declaration of Helsinki (DOH) up to date in
anticipation of its fiftieth anniversary in 2014.
The Expert Conferences convened in Cape
Town, South Africa, Tokyo, Japan and
Washington, DC, brought together experts
in ethics, members of the medical profes-
sion, educators and governmental officials
to provide input.
The conferences are part of the multi-year
effort by the World Medical Association to
examine the DOH to determine if changes
are needed.
In examining the DOH for potential
changes the WMA has focused on trans-
parency and on obtaining a diversity of
opinions from experts around the world.
At this meeting, we see the culmination of
many hours’ work by the workgroup, and
especially the facilitating group, who had
the unenviable task of taking mountains of
comments and distilling them into a new
more understandable document.
In addition, the transparency of the process
that encouraged involvement by experts in
the field and the public is an affirmation
that the end product will preserve the DOH
as the gold standard for ethical principles in
research involving human subjects.
Second, the challenge of noncommunicable
disease and the social determinants of health
The social determinants of health are the
conditions in which people are born, grow,
live, work and age; and the societal influ-
ences on these conditions.
They are major influences on both quality
of life, including good health, and length of
disability-free life expectancy.
The primary responsibility for addressing
the social determinants of health is that of
government and society.
In March I attended the Institute of Health
Equity (IHE) which makes recommenda-
tions for actions and provides analysis in
core areas of work for physicians:
1. Workforce education and training as
well as individuals and communities.
2. Government organizations and working
in partnership and as advocates.
3. Challenges and opportunities in the
health system.
The WMA believes in the importance of
health care system strengthening, universal
access and emphasizing social determinants
of health as the right approach in fighting
NCDS.
At all WHO events on this topic, the
WMA will advocate for a holistic approach
that puts social determinants of health at
the forefront of thinking about health care.
Third, the threat of climate change
Climate change due to global warming is
reality of life on our planet today.
It has health effects that are significant and
already being felt.
For example extreme heat events are more
frequent, of longer duration and more se-
vere, causing increased deaths in the tens of
thousands yearly.
Early research suggests that mitigation of
the effects of climate change may have a
link with prevention and might have sig-
nificant health benefits for both individuals
and populations.
In climate change vernacular, mitigation
and adaption are the buzzwords.
The WMA is committed to being involved
in the mitigation of climate change – that is
attempting to slow or reverse climate change
by decreasing greenhouse gas production
through implementation of green policies.
Including for example extremes of weather
such as heat events and torrential down-
pours and flooding;
Changes in insect disease vector popula-
tions, and adverse effects on food sources
brought on by droughts.
As another part of ongoing efforts to sup-
port responses to climate change, the
Address of Past President of WMA Cecil B Wilson,
October,18th
2013
Cecil B. Wilson
WMA News
162
WMA established an environmental caucus
which meets regularly in conjunction with
WMA meetings.
Last fall the caucus surveyed WMA mem-
bers to assess implementation of WMA’s
green policies within its membership.
The goal was to evaluate medical associa-
tions’ involvement in those areas and get
useful guidance for potential additional ac-
tivities.
Based on the results of the environmental
caucus survey, WMA members report they
are engaged in dealing with climate change
and have a variety of suggestions about how
further progress can be accomplished.
In conclusion, as I stated in my inaugural
address,
I still believe that in spite of the constancy
of change and the unexpected events of our
lives,
We as physicians can open new doors, share
new insights,find new cures,prevent disease
We can help our patients the world over to
live healthier, happier, longer more produc-
tive lives.
I thank you for the great honor of contrib-
uting to these ideals as WMA President
over the past year, and I look forward to
more opportunities to create a brighter fu-
ture of medicine.
The Health Secretary of the State of Ceara,
Mr. Secretary Ciro Ferreira Gomes, the
Hon. Minister of Health, Uganda, Dr. Ru-
hakana Rugunda, the outgoing President of
the World Medical Association Dr. Cecil
Wilson, the Chair of WMA Council, Dr.
Mukesh Haikerwal, the WMA Secretary
General, Dr. Otmer Kloiber, the Presi-
dent of the Brazilian Medical Association,
Dr. Florentino Cardoso, members of the
WMA, ladies and gentlemen.
It is my honour and privilege to express my
sincere appreciation to the President of the
Brazilian Medical Association,Dr.Florentino
Cardoso and his team for hosting the WMA
meeting and their warm hospitality and for
the choice for such an auspicious venue for
the meeting.Please join me in acknowledging
the hard work put in by the Secretariat (Sun-
ny, Lamine, Anna and others) ably led by the
WMA Secretary General,Dr.Otmar Kloiber
in organizing the meeting.
In a special way, I would like to thank Dr.
Cecil Wilson for having graciously men-
tored me a lot over the last 12 months about
what it means to be passionate and dedicat-
ed to getting things done and he has indeed
achieved things done. Thank you, Cecil and
I wish you all the best.
Some of you might be asking yourselves but
who I am and where I come from.
I come from Uganda, a small country in
the eastern part of Africa named which Sir
Winston Churchill in 1903 described as the
“the pearl of Africa” The weather, the cli-
mate, the evergreen scenery, the source of
the River Nile and the world’s largest popu-
lation of mountain gorillas make Uganda an
exquisitely beautiful country and you are all
invited to visit it.
This country which at one time had the
best medical school in Eastern, Central and
Southern Africa is just beginning to recover
from more than 25 years of state inspired
violence and civil conflict. It is now heart-
ening to note that it is making progress and
we are on the right track.
I have lived in that country all my life not
because I had no choice but because I made
a conscious decision to stay and make my
own contribution to making things right
especially in the medical profession.
When I qualified from the medical
school, I continued to witness the dete-
rioration in health services. I had spent
the whole of my third and fourth years
in abject fear for my life and that of my
family and friends. For 2 whole years,
reading at night was difficult because that
was when the gun shots and bombing was
worst. Getting to the teaching hospital in
the mornings for lectures to find that yet
another doctor had been killed on his way
from the hospital became the order of the
day. I still remember the helplessness I
felt as I saw many of my lecturers flee the
country and into exile.
The question on our minds as students
was, would we be able to complete
medical school. By the time, our final
year ended, Idi Amin, the former presi-
dent, had fled the country but leaving
Inaugural Address of Dr. Margaret Mungherera,
President of the WMA, October, 18th
2013
Margaret Mungherera
WMA News
163
the country in disarray. Internship was
even worse. The scarcity of resources was
gross. I  spent the whole of my intern-
ship putting up IV lines without gloves
and draining abcesses of fully conscious
patients without a local anaesthetic.
And this is when I promised myself that
I would do everything I could to be part
of the change and I am glad to say that
I have been part of it and continue to be.
As we completed our internship in 1983,
out of a class of almost 100, more than
60 of my classmates left the country in
search of greener pastures. But despite
pleas from parents, I chose to stay.
This resolve and determination enabled me
to be one of the founder members of the
Association of Uganda Women Medical
Doctors who embarked on speaking out on
the need for rural women to be able to ac-
cess reproductive health services. It is this
resolve and determination that led me ac-
cept to stand for the post of President of the
Uganda Medical Association and become
the first woman to hold that position since
its formation in 1964. I would like to thank
Richard, my husband, for being there for
me all the time.
In a country of 36 million people, I am
one of 5000 medical doctors, one of the
36 psychiatrists and one of the only 2 fo-
rensic psychiatrists the country has. But
things are slowly getting better – One of
the highlights of my time as President of
Uganda Medical Association was when I
reluctantly took up that position again in
2010 to fight for better pay for doctors and
finally convinced Government to accept
our proposal to increase the pay of doc-
tors working in rural areas by 300 percent.
It showed me that the decision I made 30
years ago to stay in Uganda was indeed a
good decision.
It has been a long journey but it has been
worth it. I have tried to take the knowl-
edge and skills I acquired during my train-
ing as a doctor and psychiatrist beyond the
hospitals and use it to reduce the suffering
of poor communities, I have sat in a grass
thatched hut with mud and wattle walls
with no lunch for days running mental
health clinics for Sudanese refugees and
internally displaced persons in Northern
Uganda, in the scorching heat with bomb-
ing and sporadic gun shots as the back-
ground music.
I have demonstrated on the streets for psy-
chosocial support for survivors of gender
based violence and I have had heated argu-
ments with the tobacco industry on nation-
al radios. I am a human rights advocate and
a women’s rights advocate. It is this passion
and determination to fight for social justice
for all that I bring to the leadership of the
WMA.
It gives me great pride to note that despite
the differing environments and circum-
stances of its members, the WMA remains
committed to providing guidance to na-
tional medical association as regards pro-
moting their professional freedom, high
medical ethical standards and professional
conduct, and advocacy for access to quality
health care for all.
During my term as President of the World
Medical Association, I will advocate for
the health of the poor and vulnerable com-
munities. Almost half of the world lives
on less than a dollar a day. Therefore we,
the Physicians of the world, through our
national medical associations have a duty
to advocate on behalf of the poor among
us – because as the famous adage goes
“If you miss the poor, you’ve missed the
point”. And there is no part of the globe
that does not have poor people who for one
reason or another cannot enjoy their ba-
sic human rights- the people who cannot
access health care, mentally ill people who
are discriminated against, and survivors
of torture and other forms of violence. As
physicians, we have been given the privi-
lege to do something about it. We can do
much as individual physicians, but we can
have wider and more sustainable impact
within our NMAs, under the umbrella of
the World Medical Association.
NMAs can ensure poor people have ac-
cess to health care by ensuring that health
systems in their countries are functional.
Universal health care or the Millennium
Development Goals cannot be achieved
where there is for example a gross shortage
of health workers or a lack of essential med-
icines. What the various stakeholders in the
Health Sector need is effective leadership
and guidance and who better suited than
NMAs to provide this leadership? However,
NMAs must ensure they have the necessary
capacity to be effective and this is where the
WMA comes in.
I salute you all, who strive, sometimes
risking your lives to minimize the suf-
fering of your communities, working in
the aftermath of natural and man-made
disasters, in places where the health facili-
ties are less than adequate. Your dedica-
tion to maintain the highest standards
in the practice of human medicine has
helped save and transform the quality of
life of individuals and whole communities
around the world.
As I conclude I would like to thank my
Minister of Health, Hon. Dr. Ruhakana
Rugunda for travelling all the way to wit-
ness my installation as president.
Through him I would like to express my
gratitude and that of Uganda Medical As-
sociation to the President of Uganda for his
support and interest in the health profes-
sion and the health sector.
Once again I would like to thank all of you
for having entrusted me with the respon-
sibility of heading this august body for the
next 12 months.
WMA News
164
Human rights, patients’ rights, professional
independence, informed consent: the fun-
damental principles of medical ethics are
universal and know no boundaries.
In 1947, doctors from 27 countries united
to set up the World Medical Association.
Their aim was to serve mankind by estab-
lishing the highest standards of ethics in
teaching, medical treatment and preven-
tion for all peoples. They did not speak the
same language, nor share the same culture
but they all had the same ideal, the same
commitment to their patients, regardless of
their religion, their social standing or their
political opinions.
The WMA has shown these past sixty years
that our will to defend the independence of
National Medical Associations and the in-
dependence of each doctor requires nowa-
days political advocacy at all levels, both
national and international.
I wish to strongly collaborate with you
all during the next three years with a
view to further cooperation in the longer
term.
It is an ethical principle that unites us:
bringing together physicians in the interests
of patients.
Dr. Xavier Deau
Current positions
• President of the European and Interna-
tional Delegation of the French Medical
Council since June 2013.
• President of the Departmental Council
of Medical Order of Vosges since 1993.
• General Secretary of the European
Council of Medical Orders (CEOM)
since 2011.
• General Secretary of the Conference of
Medical Councils from French-speaking
countries (CFOM) since 2011.
Former positions
• Council Member of the WMA since
2012.
• Vice-president of the French Medical
Council in charge of international rela-
tions from 2011 to 2013.
• Vice-president of the French Medical
Council in charge of relations with Uni-
versity from 2009 to 2013.
• President of the Medical Training
and Qualifications Department of the
French Medical Council from 2005 to
2009.
• Vice-president of the Professional Prac-
tice Department of the French Medical
Council from 2003 to 2005.
WMA President – Elect Dr. Xavier DEAU
Xavier Deau
WMA News
165
WMA News
The General Assembly meeting in For-
taleza, Brazil will be remembered for many
things. But chief among them will be that it
was the meeting where the revised Declara-
tion of Helsinki was adopted after a pro-
cess lasting two years. But it was also the
Assembly where Dr. Margaret Mungherera
was installed as the first African woman to
become WMA President.
The meeting, held at Villa Galé Cumbuco,
Fortaleza, Brazil, held from October 16th
to
20th
, was attended by more than 250 del-
egates and observers from more than 45
national medical associations (NMAs) and
other organisations. As usual the proceed-
ings opened on the first day with a meeting
of the Council.
Council
Dr. Mukesh Haikerwal, Chair of the WMA,
reported briefly on the activities of theWMA
in helping doctors around the world who get
into difficulties. The latest example was the
case of a Canadian doctor, arrested and im-
prisoned in Egypt during the recent riots,
who had just been released with the help of
the WMA and others. He also referred to
the multiple global meetings that were held
around the world, such as the G8 and the
G21. What he found very concerning was
that often the place of health care and health
was missing.‘Our role and that of the WMA
and its members is to bring to people’s notice
that it is very important to have good clinical
care, to have good healthy subjects to make
sure the agenda for economic development is
actually achieved’, he said.
The Secretary General, Dr. Otmar Kloiber,
added to an extensive written report on ac-
tivities during the year, by highlighting the
European Union directive on clinical trials,
which related to the Declaration of Hel-
sinki. This was now being converted into
a regulation and it would have a direct ef-
fect as a law on all European countries. He
said the WMA was disappointed that in
the new regulations there was no longer a
requirement to have the approval of ethics
committees before a clinical trial could start.
The requirement to have ethics commit-
tees involved had now been put back into
the proposal as the WMA had requested,
but not in a way it would like to have seen.
However he was hopeful that there would
be further changes so that any proposal for a
trial would have to be positively considered
by an ethics committee.
A second issue in the regulation, which was
of global importance, related to the dual use
of samples and data in clinical studies. He
said the WMA was convinced that for all the
research carried out the informed consent of
participants was needed.However a problem
might occur when there was a second use
for the samples from the study and patients
might not be able to be reached for a second
informed consent. If that was not possible,
the Declaration of Helsinki now said that an
ethics committee had to give permission to
use that data. But major research groups had
been lobbying the European Parliament to
come to a different conclusion,by saying that
there should be a broad consent for the sec-
ondary use of samples or data in bio banks or
from research projects. The WMA believed
that would undermine informed consent
completely because it would not allow for
the subjects in a study to exercise their self-
determination correctly. He said the WMA
would like to see a solution closer to that
suggested in the Declaration of Helsinki.
Discussions were continuing and the WMA
would continue to monitor the situation.
Emergency Motions
Notice was given to the Council of three
emergency motions – on the Prohibition of
Chemical Weapons, Chemical Riot Con-
trol Agents and Health Care in Syria.It was
agreed that all three should be considered as
a matter of urgency.
Finance and Planning
Committee
The committee met under the Chairman-
ship of Dr. Leonid Eidelman (Israel Medi-
cal Association).
Financial Reports
The Treasurer, Dr. Frank-Ulrich Montgom-
ery, introduced the audited financial state-
ment for 2012, and the Budget for 2014.
Mr Adolf Hällmayr, the Financial Advisor,
highlighted some of the main points of the
expenditure and income figures for 2012
and went through the Budget for 2014.
He said that due to the on-going negative
effects of inflation on the expenses an ade-
quate increase in income would be necessary
to obtain balanced results and to guarantee
financial stability. To this end discussions
had already started. It was agreed that the
reports be forwarded to Council and then
64rd
WMA General Assembly and 195th
/196th
Council Sessions
Nigel Duncan
166
Declaration of Helsinki COUNTRYWMA News
to the Assembly for adoption. Mr Hällmayr
also reported on the situation on member-
ship dues and categories. A brief debate fol-
lowed on a proposed new dues structure. It
was agreed to recommend that the Council
should establish a workgroup to review the
proposal for new structure of membership
dues and report back
Strategic Plan
Dr. Kloiber mentioned the current difficulty
with raising sponsorship money, although
there were still sponsored projects running.In
the areas of ethics and advocacy, the WMA,
in collaboration with the World Health Pro-
fessions Alliance,would be hosting the World
Health Professions Regulation Conference
in May 2014. There was a global trend for
regulation to be taken over by governments
and this was a critical issue that required the
WMA’s attention. He also recognized that
the Junior Doctors Network had become very
active in the WMA and this was a benefit in
terms of new ideas as well as increasing the
visibility of the Association.
Business Development Group
Professor Vivienne Nathanson (British
Medical Association) reported on the first
meeting of the business development round
table recently held in London. Six of the
12 organisations that had agreed to join
the group had attended and it was agreed
to meet again. A paper was being prepared
about other ideas for producing non dues
revenue. The Group was planning its next
round table in Tokyo in conjunction with
the Council session.
Future WMA Meetings
An oral report was given about the Council
meeting due to be held in Tokyo from April
8–12. It also agreed that at the next General
Assembly in Durban,South Africa in Octo-
ber 2014 the theme of the scientific session
would be ‘Universal Access to Health Care
after MDGs’. The committee agreed that
the invitation from the Norwegian Medical
Association to host the 200th
Council Ses-
sion in 2015 in Oslo be accepted.It was also
agreed that the Council recommend to the
Assembly that the theme of scientific ses-
sion for General Assembly in Moscow 2015
be medical education.
Declaration of Helsinki – 50th
Anniversary
Dr. Eidelman gave an oral report about
plans for an event in Helsinki to celebrate
the 50th
anniversary of the Declaration of
Helsinki in May or June 2014. Dr. Heikke
Pälve (Finish Medical Association) ex-
plained that the event would begin with a
scientific session in the morning followed
by a celebration attended by the President
of Finland. He said that suitable dates and
venues were still being considered
New Members
The Committee considered applications for
membership from the Medical Chamber of
Montenegro, the Ordre National des Mé-
decins du Cameroun,the Sudanese Medical
Association and the Federazione Nazionale
degli Ordini dei Medici Chirurghi e degli
Odontoiatri, Italy. It was agreed that these
be forwarded to Council for adoption by
the Assembly. Dr. Kloiber reported that the
Association of Hungarian Medical Societ-
ies (MOTESZ) had agreed to be replaced
by the Hungarian Medical Chamber in
WMA membership and this matter would
be considered by Council.
Socio-Medical Affairs
Committee
The committee met under the Chairman-
ship of Sir Michael Marmot (British Medi-
cal Association).
Health Care in Danger
Prof. Nathanson, Chair of the workgroup
on Health Care in Danger, reported on the
activities of the group. She said the British
Medical Association had agreed to work
with the International Committee of the
Red Cross on a toolkit looking at the ethical
dilemmas faced by doctors in situations of
armed conflicts and other situations of vio-
lence. She also reported on the workgroup’s
decision to work on the subject of psychia-
try and quality of care, and in particular
issues related to whether some psychiatric
treatment without the consent of the indi-
vidual amounted to torture or ill treatment.
Violence Against Women and Girls
The Chair of the Committee put forward
proposals for implementing the proposed
resolution on violence against women and
girls. He suggested exploring opportuni-
ties to collaborate with global organisations
working in this area, such as the Global
Foundation to End Domestic Violence,
initiated by Baroness Scotland. The Ameri-
can Medical Association referred to the US
organisation, Futures without Violence, and
said they would make contact with them. It
was also suggested that the WMA might
organise a side-event on this issue at the
World Health Assembly 2014, possibly in
cooperation with the International Federa-
tion of Medical Students Association and
the International Federation of Gynaecolo-
gy and Obstetrics.A third idea was to invite
national medical association members to
report to the secretariat on their initiatives
in relation to violence against women in or-
der to acquire an overview of their involve-
ment in this area.The Indian and Australian
Medical Associations also reported on their
activities on this issue.
Right to Reparation of Victims of Torture
The Committee considered a proposed
Statement on the Right to Reparation of
Victims of Torture proposed by the Danish
Medical Association. The statement urged
national medical associations to work with
other organisations to ensure the reparation
of victims of torture in view of concern at the
167
WMA News
continued use of torture in many countries
throughout the world. It was proposed and
agreed that the title of the Statement should
be amended to use the word ‘rehabilitation’
rather than ‘reparation’and it was agreed that
the document should be forwarded to Coun-
cil for adoption by the Assembly.
Human Papillomavirus Vaccination
The Committee considered a proposed
Statement on Human Papillomavirus Vac-
cination.Dr.Ardis Hoven (American Med-
ical Association) said the Statement had
been circulated for comments and these had
been taken into account. The safety, efficacy
and value of a vaccine were well known.
Each nation would have its own health pri-
orities and the unique opportunity to pre-
vent HPV associated cancers merited con-
sideration. A brief debate followed, when it
was argued that the WMA should be very
cautious about getting involved in specific
medical issues. However Dr. Hoven replied
that a stand-alone Statement was needed
because there was little common knowl-
edge, even among physicians, about what
this vaccine could do and what it could pre-
vent. A motion to defer the document was
defeated and it was agreed that the State-
ment be approved by the Council with the
recommendation that it be forwarded to the
General Assembly for adoption.
Fungal Disease Diagnosis and Management
Dr. José Luiz Gomes do Amaral (Brazil
Medical Association) proposed a State-
ment on Fungal Disease and Management.
He said its purpose was to raise the atten-
tion of national medical associations to the
problem of fungal disease, which was often
considered not as important as tuberculo-
sis, malaria or AIDs. But from the data the
global burden of fungal disease compared to
these other diseases. In a brief debate, it was
decided to remove the statistics from the
document because they would quickly go
out of date and undermine the fundamental
message of the Statement.It was agreed that
the proposed Statement be revised and be
submitted to the Council for consideration.
Ethical Guidelines for Recruitment of Physi-
cians
The Committee considered a proposed revi-
sion to the WMA statement on the Ethical
Guidelines for Recruitment of Physicians.
Prof. Nathanson said none of the principles
had been changed but it had merely been
updated. It was agreed that the document
be circulated to NMAs for comments.
Non-Commercialization of Human Repro-
ductive Material
A proposed revision of the WMA Resolu-
tion on the Non-Commercialization of Hu-
man Reproductive Material was put forward
by Dr. Eidelman. In view of the fact that the
revisions introduced substantial changes, it
was agreed that the document should be cir-
culated to NMAs for comment.
Ethical Implications of Reality TV for Physi-
cians
A proposed Statement on the Ethical Im-
plications of Reality TV for Physicians
was presented by the Israel Medical As-
sociation. It argued that these programmes
were a form of experimentation on human
beings, putting enormous pressure on par-
ticipants in the drive to win audiences.Such
shows were now popular around the world,
and the WMA should have some ethi-
cal policy for physicians involved in these
programmes. This led to a lengthy debate
in which a number of speakers argued that
this was not an appropriate subject for the
WMA to consider.On a vote it was decided
that the document should be circulated to
NMAs for comment.
The Role of Physicians in Preventing the Traf-
ficking with Minors and Illegal Adoptions
The Committee considered a proposed
Statement on the Role of Physicians in Pre-
venting the Trafficking with Minors and Il-
legal Adoptions. Introducing the document,
Dr.Fernando Rivas Navarro (Spanish Medi-
cal Association) said the problem of chil-
dren trafficking and illegal adoptions was an
overwhelming one. It was estimated by the
United Nations Office for Drugs and Crime
that an average of 1.2 million children were
trafficked every year.A good number of them
would need genetic identification to find out
who they are and where their families were,
or even which were their countries of origin.
In 2006 a pilot program, DNA-Prokids, was
started in Guatemala, and extended to Mex-
ico. In 2009 the University of North Texas
Health Sciences Center joined with the Uni-
versity of Granada to launch the program in
as many countries as possible, basically Latin
America and Asia.Since the program started
a total of 9330 samples had been analyzed.
Among these, 697 positive associations had
been made and most of these children had
been returned to their families or were in the
legal process of doing so.In addition 221 ille-
gal adoptions had been detected and avoided.
The intention of the proposed document was
to establish a professional observatory within
the WMA and, led by the Organización
Médica Colegial de España,to learn in detail
about the role of physicians in the medical
attention of unidentified children and adop-
tion.Such a move would also help to find out
how physicians could play a preventive role
by warning adopting families and by collab-
orating with their own national authorities.
Aesthetic Procedures
Two papers were received by the committee,
the first a proposed Statement on Aesthetic
Procedures for Minors presented by the
Israel Medical Association and a second,
a proposed Statement on Aesthetic Treat-
ment in general proposed by the Swedish
Medical Association. Proposing the general
paper, Tomas Hedmark (Swedish Medical
Association) said that aesthetic treatments
had become more common in recent years
and were performed by practitioners with
widely different backgrounds. Some were
168
WMA News
physicians, but many were not. In Sweden
the view seemed to be that aesthetic treat-
ments without medical indication should
not be considered as health care. He be-
lieved that the WMA should develop policy
applying to all practitioners, physicians and
others, who performed these treatments.
One reason for this was that the negative
effects of aesthetic treatments would end
up in regular health care where they would
be handled by physicians. The committee
agreed that the Israel and Swedish Medical
Associations should get together to consid-
er if the two documents could be combined
and then circulated for comment to NMAs.
Statement on Variations of Human Sexuality
A proposed Statement on Normal Varia-
tions of Human Sexuality was proposed
jointly by the German Medical Association,
the Conseil National de l’Ordre des Méde-
cins, and the British Medical Association.
After the paper had been proposed by Dr.
Xavier Deau there was a lengthy and pas-
sionate debate about a proposal to delete
the word ’normal’ from the document and
substitute it with the word ‘natural’. Some
speakers questioned whether the subject of
the Statement was an urgent matter and said
that in several countries being homosexual
was illegal. But supporters of the Statement
argued that widespread concern had been
expressed by professional medical societies
about the use of conversion procedures, as
well as the fact that in many regions being
homosexual was still a reason for torture,
jail or execution. It was eventually decided
that the proposed Statement be amended as
proposed and sent to the Council with the
recommendation that it be forwarded to the
General Assembly for adoption.
The Role of Physicians and NMAs, Social De-
terminants of Health and Health Equity
The Committee considered a proposal from
the Canadian Medical Association to orga-
nise a symposium of interested constituent
members in to develop plans to address the
social determinants of health and health
equity. NMAs were invited to provide their
views on the proposal to the Canadian
Medical Association or to WMA secretari-
at in the coming weeks and a more detailed
proposal would be brought to the Council
at its next session in Tokyo, April 2014.
Brazilian Medical Association
The Committee considered a proposed Res-
olution in Support of the Brazilian Medi-
cal Association introduced by Dr. Miguel
Jorge. He explained that the Brazilian
Government had introduced a programme,
“Mais Médicos”, to give recognition to Bra-
zilian citizens who had studied in Cuban
medical schools. They received diplomas
that were not valid even in Cuba. The pro-
gramme was created by the Government in
order to recognise those diplomas and put
these people to work in remote areas of the
country. There were some places where no
physicians were working because of a lack
of health infrastructure. In response to the
reaction of the Brazilian Medical Asso-
ciation, the Government had changed the
main purpose of the programme and aban-
doned the idea of using its programme to
give validity to these Brazilian physicians
who gained their diplomas outside Brazil
and changed the focus to import physicians.
It was expected that there would be around
12,000 Cuban physicians working in Brazil.
From these 12,000 physicians some hun-
dreds had arrived and were starting to work.
The problem was that these physicians and
others covered by the programme were not
being employed by the Government re-
specting the labour laws. They would just
receive pocket money and some support to
work in the cities. Those from Cuba would
not receive the same amount of money as
others. Their payments would be sent from
the Brazilian Government to the Cuban
Government. These physicians were not al-
lowed to bring their families to Brazil.Most
of the physicians that had been imported
were not working in remote areas but had
gone to work in the big cities and there was
some concern about their prescribing com-
petence.The committee approved the Reso-
lution and agreed to send it to Council with
the recommendation that it be forwarded to
the General Assembly for adoption.
Advocacy
Dr. Jeff Blackmer (Canadian Medical As-
sociation) reported on the activities of the
Advocacy Committee, which had met the
day before and discussed two main items.
The first related to a media event to be
scheduled in conjunction with the celebra-
tion of the 50th
anniversary of the Declara-
tion of Helsinki in 2014.The second referred
to plans for an advocacy training session
during the scientific session to be held in
Durban, South Africa in October 2014. It
was agreed that the Committee would pro-
vide its support to the South African Medi-
cal Association with a view to including an
advocacy component in the session.
Emergency Resolutions
Prohibition of Chemical Weapons
A proposed Resolution on the Prohibition
of Chemical Weapons was introduced by
the Turkish Medical Association. After a
brief debate it was decided that the Reso-
lution be revised, in particular by removing
the references to countries in the text. The
British Medical Association volunteered to
lead the revision and submit the result to
the Council for consideration. It was agreed
that a workgroup be set up with a man-
date to develop a comprehensive policy on
chemical weapons and riot control agents,
as referred to in the second emergency reso-
lution.
Chemical Riot Control Agents
The second emergency Resolution call-
ing for the Prohibition of Chemical Riot
Control Agents was also introduced by the
169
WMA News
Turkish Medical Association with reference
to the recent disturbances in Turkey. How-
ever, the Resolution failed to gain support.
Instead it was agreed that it would be con-
sidered by the workgroup.
Health Care in Syria
The Committee considered the proposed
Emergency Resolution on the Healthcare
Situation in Syria. Prof. Nathanson said
that attacks on civilians and on hospitals,
clinics and those attempting to provide care
seemed to be getting worse every day. This
was now a crisis situation. Not only were
huge numbers of the Syrian population
fleeing the country, but those remaining
and who were ill were not getting access to
healthcare and doctors and others looking
after them were at serious risk.The commit-
tee agreed that the proposed Resolution be
approved by the Council with the recom-
mendation that it be forwarded to the Gen-
eral Assembly for adoption.
Medical Ethics Committee
The committee met under the Chairman-
ship of Dr. Heikke Pälve (Finland Medical
Association).
Declaration of Helsinki
The first of several lengthy debates then took
place about revisions to the Declaration of
Helsinki. Dr. Parsa-Parsi (German Medi-
cal Association), Chair of the workgroup,
thanked the members of the working group,
including ethics advisors,for their hard work
toward the shared goal of revising the docu-
ment to promote the highest standards in
medical ethics.The revised document repre-
sented input from many expert stakeholders
and organizations throughout the interna-
tional community, provided over a two year
period, in an open and collaborative process.
All comments and suggestions had been
carefully and systematically considered by
the workgroup in the drafting process. Prof.
Urban Wiesing, ethics adviser to the work-
group, gave an overview of the changes be-
ing proposed. He reported on the revision
process and the 150 comments received. It
had been the most intensive public debate
on the revision of the Declaration that had
ever taken place.The workgroup had decided
at the outset that the character of the Decla-
ration should remain, that its length should
stay about the same and that it should re-
main distinct from other guidelines. He said
the main changes were to introduce more
precise wording, a more readable structure,
revised paragraphs on vulnerable groups,
post study arrangements and research ethics
committees and for the first time to mention
the issue of compensation. The workgroup
had decided to give the Declaration a new
structure with a new order and some merg-
ing of paragraphs. He explained why the
revisions contained no list of specific vul-
nerable groups. Referring to changes to the
post study arrangements, he said that in the
2008 version of the Declaration the wording
was vague.The workgroup was now propos-
ing more precise wording and in particular
to state clearly the responsible institutions –
sponsors, researchers and host country gov-
ernments. For the first time norms had been
set out for members of research ethics com-
mittees, that they should be duly qualified.
The introduction of compensation was a big
step in the history of the Declaration. Until
now compensation had not been mentioned
for people who were harmed during clini-
cal trials. Now compensation and treatment
for subjects who were harmed was being de-
manded and this improved the protection of
participants, in particular in poor countries.
He explained the reference for the first time
to biobanks. The general principles of in-
formed consent complied for the collection,
storage and reuse of samples.Turning to the
issue of placebos, he said there had been no
ethical change compared to the 2008 Dec-
laration. But a more systematic approach
had been proposed. Now a proposal that any
control less than the best proven interven-
tion was addressed. He accepted that the is-
sue of placebos was controversial. Another
big step was the proposal for every research
study to be registered, not only clinical stud-
ies.
Dr. Jeff Blackmer, the WMA’s ethics ad-
viser, explained in more detail the proposed
changes, going through the document para-
graph by paragraph.The Chair then opened
the meeting to invite discussion and pro-
posed amendments.The Royal Dutch Med-
ical Association asked for clarification about
why participants in medical research were
‘encouraged’in parts of the Declaration and
not imposed. Dr. Blackmer explained that
the WMA could not impose things on oth-
ers involved in research. Dr. Kloiber added
that the WMA should refrain from making
rules for other groups. Concern about the
issue of compensation and the possibility of
abuse was raised by the Ugandan Medical
Association. Professor Weising explained
the scope and intent of the paragraph and
further clarification was provided from two
members of the workgroup.
The main discussion took place on para-
graph 20 concerning medical research with
a vulnerable group and the issue of benefits.
The South African Medical Association
expressed concern about the subject of ‘ad-
ditional benefits’ in the paragraph, espe-
cially with respect to developing countries,
and the possibility of coercion and undue
inducement. The Indian Medical Associa-
tion supported this concern. Prof. Wiesing
explained the rational of the workgroup in
including this language. Dr. Blackmer also
described the advantages and disadvantages
of this language. Medical research with a
vulnerable group was only justified if the
research was responsive to the health needs
or priorities of this group and the research
could not be carried out in a non-vulnerable
group. In addition, this group should stand
to benefit from the knowledge, practices
or interventions that resulted from the re-
search. A proposal was made to delete the
final two sentences in paragraph 20 relating
to a group receiving a fair level of additional
benefits if certain conditions were met and
170
WMA News
on a vote it was agreed that the two sen-
tences should be deleted.
On paragraph 25, relating to informed
consent, the French and Uruguay Medical
Associations expressed concern about how
this paragraph might relate to the use of
placebo. Prof. Wiesing reviewed the history
of debate on informed consent over the past
two revision processes and the reasons be-
hind the way the current text was written. A
motion to amend paragraph 25 by addition
was not accepted.
Further debates took place about the re-
quirement to obtain informed consent for
the reuse of human material or data and
on the issue of use of placebos, but without
any further amendments being agreed. At
the end of the debate, the proposed revised
Declaration, as amended by the committee,
was approved for forwarding to Council
and the General Assembly with the recom-
mendation that it be adopted.
Health Databases
The Committee received the oral report of
the workgroup on Health Databases from
Dr. Jon Snaedel (Iceland Medical Associa-
tion). He noted that there were several op-
tions for defining the scope of the WMA
work in this area. The committee recom-
mended that the workgroup be instructed
to continue its work on the broad concept
of health databases.
Associate Members
Junior Doctors Network
Dr. Thorsten Hornung, immediate past
Chair of the Network, gave an oral report
on behalf of the Junior Doctors Network,re-
porting on its activities during the past year.
A new team of officers had been elected at
the Network’s meeting on Tuesday. In par-
ticular he spoke about the JDN’s work on a
policy paper about physician well-being. He
talked about junior doctors having to live in
places with no running water and being on
call all the time and not going home for 30
days in a row. He said there was much stress
among physicians and yet they were a group
who should practice what they preached.
He said support structures were needed.
Dr. Daniel Johnson, past President of the
WMA, referred to the system in most US
states where impaired physicians – physi-
cians with alcohol or drug problems – were
helped to return to practice. The intent was
not to keep these physicians from being able
to practice, but to correct the impairment
and restore them to practice. There was a
shortage of physicians and this was the best
approach, both from the physicians’ point of
view and the patients. He suggested that the
JDN consider introducing such a suggestion
into their paper.
Chair
Dr. Guy Dumont, Chair of the Associ-
ate Members since 1993, said he would be
retiring as a physician next year and would
be stepping down as Chair of the Associate
Members. He was thanked for his work and
received a standing ovation.
Scientific Session
The theme of the session was ‘Life styles
and non communicable chronic diseases’.
Opening the session, Dr. Margaret Mungh-
erera,President elect of the WMA,said that
the adoption of abnormal lifestyles among
populations had had immeasurable adverse
impact on the health and survival of peoples
of the world,much greater than that created
by the epidemics of communicable diseases
such as the plague of the middle ages,tuber-
culosis and syphilis.
‘The insidious onset of NCDs is elusive’,she
said. ‘They spread silently through the pop-
ulations and they kill or maim quick when
they emerge. The behavioural contributory
factors are known and include inadequate
physical activity, cigarette smoking, un-
healthy eating habits and excessive alcohol
ingestion’.
She said that NCDs were cheaper and eas-
ier to prevent and that was where most of
the focus and therefore the resources should
go. And the targets should include children.
‘Rather than focus on a few NCDs, the ap-
proach needs to be holistic and therefore
strengthening health systems, universal
health care and addressing social deter-
minants is where the emphasis should be
placed. For instance, effective preventive
and health promotion programmes require
adequate numbers of motivated and skilled
health workers’.
Speakers during the day talked about diet,
physical activity, tobacco and alcohol. The
opening presentation on the social deter-
minants of health was given by Sir Michael
Marmot (British Medical Association),who
spoke about health data around the world
compared to social gradients. He talked
about data from Brazil about cardiovascular
disease showing that the more deprived the
district the higher the mortality.He referred
to data on diabetes based on social gradients
and talked about the data on obese children
in England and its relationship to the social
determinants of health. The challenge was
to deal with the social determinants of the
risk factors involved.He looked at how Bra-
zil had tackled social inequality and found
that they had made progress. And he posed
the question about what doctors could do
about these problems. Among the areas
where they could get involved were educa-
tion and training, working with individuals
in communities, the health service as an
employer, working in partnership with oth-
ers, and working with the health system.
Dr. Howard Bauchner, editor in chief of
the Journal of the American Medical As-
sociation, spoke about controversies over
diet and health in the United States and
171
WMA News
the worldwide epidemic of obesity. He said
there had been a seismic shift from organic
to processed food. But he said there were
very few clinical trials that could help them
understand what their public health recom-
mendation should be. Tremendous strides
had been made in the US on cardiovascular
disease. But as people have lived longer Al-
zheimer’s Disease and cancer had become
more important. He spoke of the progress
made in dealing with HIV Aids, but said
that chronic renal disease had skyrocketed,
as had drug abuse. He talked about the con-
troversy over salt and the amount of salt that
anyone should consume. And he said that
the only common factor that made a diet
successful was adherence. On the politics
of public health, he said that every country
struggled with how much they should dic-
tate to its citizens about lifestyle.
Dr. Luiz Claudio Castro (Brazilian Medi-
cal Association), a professor of paediatrics,
spoke about childhood obesity. He said that
they had to promote health and well-being
at childhood in order to assure quality of life
in future stages. Obesity disrupted three in-
stances of well-being, physical, mental and
social. It had to be managed as a disease and
not just a situation.Yet with childhood obe-
sity they had lots of questions but still few
answers. There were some certainties – that
childhood obesity had reached epidemic
levels. But they had to believe that this
could be reversed.
Dr. Jeremy Lazarus (American Medical
Association) spoke about physicians as role
models for physical activity.He said physical
activity was both enjoyable and rewarding.
He spoke about competing in marathons
and said he had completed 13 of them. He
and his wife rode a tandem and this was
good for relieving stress. He said it was im-
portant for physicians to act as role models
not only for their patients, but also for their
families and their communities. He enjoyed
the challenge of pushing himself and said
it was important that physicians thought
about their own physical and mental health.
Dr.Carlos Serrano Jr.(Brazilian Medical As-
sociation),a cardiologist,spoke about cardio-
vascular risk reduction as a result of physical
activity and health promotion. The concept
of taking exercise for heath was centuries old.
He said physicians should recommend their
patients to take exercise. But to educate their
patients about health and well-being and for
physicians to convince their patients about
the benefits of well-being it was important
for physicians themselves to exercise.
The session on Tobacco and Public Health
opened with Dr. Heikki Pälve (Finish
Medical Association) talking about the
Finish Tobacco Policy. He stressed the
need for co-operation to achieve any re-
sults. Finland’s battle against tobacco began
in the 1960s when the medical association
put forward proposals. But it had to persist
before its policies began to take effect with
legislation introduced in the 1970s. But it
was rather the intense discussion leading up
to the legislation which caused many people
to quit smoking rather than the legislation
itself. He said there must be no compro-
mises with the tobacco industry. The aim
now was a tobacco-free Finland by 2040.
Was this possible, he asked. After their ex-
periences of already achieving things people
did not think were possible, he thought the
answer was a definite yes.This was followed
by Alberto Araujo (Brazilian Medical As-
sociation) talking about The Role of Health
Professionals on Tobacco Control Policies.
The final session on alcohol began with
Dr.  Mervi Kattelus (Finish Medical As-
sociation) talking about European Union
Policies Against Alcohol Related Harm
and the session concluded with Dr. Sérgio
de Paula Ramos (Brazilian Medical As-
sociation) talking about Alcohol Abuse by
Adolescents.Dr.Ramos said that there were
2.5 million deaths a year as a result of al-
cohol. For young people it was the number
one risk factor. He talked about the adver-
tising of alcohol in Brazil and said that the
alcohol industry was not concerned with
ethics or public health.
Council
Council reconvened on the third day of the
meeting to consider reports from the com-
mittees held on the first day.
Medical Ethics Committee
Declaration of Helsinki
The Council considered the revised Dec-
laration of Helsinki as amended by the
Medical Ethics Committee. This led to a
further brief debate on the document, but
no further amendments were made and the
Council approved the revised Declaration
for sending to the Assembly for adoption.
Health Databases
The Council agreed that the membership
and mandate of the workgroup on health
databases be extended to include the issue
of biobanks.
Person Centred Medicine
It was agreed to recommend to the As-
sembly that a proposed Statement on
Person Centred Medicine be circulated to
NMAs for consideration. The paper, from
the Iceland Medical Association, calls for
a shift in the focus of health care from the
providers and healthcare system to the in-
dividual.
Women’s Rights to Healthcare and How that
Relates to Mother and Child HIV Infection
The Council agreed that a proposed Resolu-
tion submitted by the South African Medi-
cal Association should be sent to the As-
sembly for adoption.
Forensic Investigations of The Missing
The Council agreed that a revised Statement
on Forensic Investigations of The Missing
be sent to the Assembly for adoption.
172
WMA News
Finance and Planning Committee
Membership
Dr. Kloiber said that since 1988 the As-
sociation of Hungarian Medical Societies
(MOTESZ) had been a member of the
WMA. However the Association had ex-
perienced problems in maintaining mem-
bership and the WMA had now received a
request from the Hungarian Chamber,open
to all physicians in Hungary, to become the
WMA member.The Council recommended
to the Assembly that the Hungarian Medi-
cal Chamber should be accepted as a mem-
ber of the WMA.
World Medical Journal
Dr. Peteris Apinis, the editor of the Journal,
said next year would be the 60th
anniversary
of the Journal. He talked about the possibil-
ity of changing the journal to an electronic
journal and indicated that it was time for a
younger person to take over as editor.
Past Presidents and Chairs Network
Dr. Kloiber reported on the newly-set up
Network of Past Presidents and Chairs. It
had met for the first time the previous day
when terms and reference were discussed on
the basis of the network acting as a sound-
ing board for the Council. In an election
Dr. Dana Hanson (Canada) was elected
Chair, Dr. Kgosi Letlape (South Africa)
Vice Chair and Dr. Jon Snaedal (Iceland)
Secretary.
Socio-Medical Affairs Committee
Human Papillomavirus Vaccination
Dr.Heikke Pälve referred to the document’s
recommendation that there should be ‘HPV
vaccination for all children starting at age
11 or 12, for all females age 13 through 26,
for all males age 13 through 21 (any male
may be vaccinated through age 26), for all
immunocompromised patients who are
age 22 through 26, and for men who have
sex with men who are age 22 through 26’.
He suggested that this was far too detailed
and should be deleted from the paper. The
Council agreed to delete the sentence and
substitute it with the sentence ‘Recommend
HPV vaccination for all appropriate popu-
lations’and to forward the Statement to the
Assembly for adoption.
Fungal Disease Diagnosis and Management
The Council agreed that the proposed
Statement should be forwarded to the As-
sembly for adoption.
Brazilian Medical Association
The proposed Resolution in Support of the
Brazilian Medical Association was agreed
and it was recommended that it be forward-
ed to the Assembly for adoption.
Prohibition of Chemical Weapons
Prof.Nathanson said that the two papers on
the Prohibition of Chemical Weapons and
the Prohibition of Chemical Riot Control
Agents had now been combined into one
document. Reference to specific countries
had been deleted and a final recommenda-
tion had been added, urging urges states
using chemical agents in riot control situa-
tions to carefully consider and minimise the
risks and to, wherever possible, refrain from
such use. The Council approved the Resolu-
tion and it was agreed to forward it to the
Assembly for adoption.
Health Care in Syria
The Council approved the Resolution and
agreed to forward it to the Assembly for
adoption.
Variations of Human Sexuality
A further debate took place on the pro-
posed Statement after Dr.Leonid Mikhay-
lov (Russian Medical Society) proposed
that the word ‘natural’ be deleted from the
document. However several speakers sup-
ported keeping the word ’natural’. Prof.
Nathanson said it was completely unac-
ceptable to argue that in most of the world
this was a question for debate as a scien-
tific issue. It would be unacceptable for the
WMA to have a document on homosexu-
ality that did not make it quite clear that
this is a natural variation of sexuality. Af-
ter the proposal to delete the word’ natu-
ral’ failed to find a seconder, the Council
agreed the Statement and recommended
that it should be forwarded to the Assem-
bly for adoption.
Presidency
Dr.Haikerwal, Chair of Council, report-
ed that a letter had been received from
the Indian Medical Association request-
ing that the 2010 suspension imposed on
Dr.  Ketan Desai’s inauguration as Presi-
dent should be lifted. He said the Indian
Medical Association had submitted a mo-
tion calling for a date to be set for Dr. De-
sai’s Presidency. He explained to Council
the background to the case, arising from
Dr.  Desai’s arrest and imprisonment in
2010 which prevented him from attending
the Vancouver Assembly. Dr. Haikerwal
said that the charges against Dr. Desai had
since been withdrawn and he was asking
Council to recommend to the Assembly
that the suspended inauguration be lifted
and to recommend a date when Dr. De-
sai should take up his Presidency. Dr. Ajay
Kumar (Indian Medical Association) said
that Dr. Desai’s arrest was a result of him
becoming too powerful a medical leader
for the Indian Government. After a further
debate, the Council decided to recommend
to the Assembly that the suspension of
Dr.  Desai’s inauguration should be lifted
and that the question of when this should
take place should be considered at the
Council meeting in Tokyo in April 2014 to
be confirmed at the next Assembly meet-
ing in Durban in October 2014.
173
WMA News
General Assembly
Ceremonial Session
The Assembly was called to order by the
Chair,Dr.Mukesh Haikerwal and a roll call
and introduction of delegates and observers
was carried out by the Secretary General,
Dr. Kloiber.
Welcome addresses were given by Secretary
Ciro Ferreira Gomes,Health Secretary of the
State of Ceará,and Dr.Florentino de Araújo
Cardoso Filho, President of the Brazilian
Medical Association, before Dr. Haikerwal
paid a tribute to the outgoing WMA Presi-
dent, Dr. Cecil Wilson as a thoughtful, hon-
ourable and diligent man. Dr. Wilson then
delivered his valedictory address. (p. 161)
Dr. Margaret Mungherera, President of the
Uganda Medical Association, was then in-
stalled as the 64th
President of the WMA,
and gave her inaugural address. (p. 162)
General Assembly
Plenary Session
Election of President for 2014/15
Dr. Xavier Deau, President of the European
and International Delegation of the French
Medical Council, was elected unopposed as
President of the WMA for 2014/15. Thank-
ing the meeting for his election,Dr.Deau said
that for several decades the French Council
had built up close links with its European in-
ternational counterparts. Nowadays this in-
ternational commitment was more important
than ever. National and global health were
becoming more and more political issues and
the French Council wanted the WMA to
be the leader in anticipating the changes in
medical practice while preserving the quality
of doctors and access to health care.
Use of the Death Penalty
The proposed Statement on support for
the United Nations Resolution for a Mor-
atorium on the Use of the Death Penalty
was put forward for adoption. Dr. Jeremy
Lazarus (American Medical Association)
said the AMA delegates would be voting
against this Statement. Although they re-
spected the views of all their colleagues,
the AMA did not take a position for or
against the death penalty or on the issue
of a moratorium. They believed these were
issues for the individual moral decision of
physicians, and physicians in the US were
deeply divided on this matter. The Chair
explained that the Statement would re-
quire 93 votes, a three-quarters majority,
for adoption. On a vote, the Statement was
carried by 94 votes to 25 with four absten-
tions. (p. 179)
Declaration of Helsinki
The revised Declaration of Helsinki was
then introduced and Dr. Parsa-Parsi, Chair
of the workgroup, Professor Wiesing and
Dr. Blackmer explained to the Assembly
the revision process that had been under-
taken for the past two years and the de-
tailed changes that were being proposed.
Prof. Wiesing explained the details of the
new compensation proposals included in
the Declaration and the revised paragraph
on the use of placebos, which he said would
always be controversial. Dr. Blackmer talk-
ed about the issue of research on vulner-
able groups. The only discussion that fol-
lowed concerned paragraph 33 on the use
of placebos. Several delegates spoke against
the paragraph and said they could not ac-
cept the revised wording. But on a vote the
paragraph was approved by 110 votes to
10. On a further vote, the revised Declara-
tion of Helsinki was adopted with a strong
three-quarters majority as required. (p. 199)
Members of the workgroup were applauded
for their work.
Women’s Rights to Healthcare and How that
Relates to Mother and Child HIV Infection
The Resolution on Women’s Rights to
Healthcare and How that Relates to Moth-
er and Child HIV Infection was adopted
with one small amendment to add the word
‘unwanted’ to the following recommen-
dation for campaigns to ‘eradicate myths,
stigma and stereotypes that might degrade
or dehumanise women. This must include
campaigns against genital mutilation and
forced adolescent marriages and unwanted
pregnancies.’ (p. 183)
Forensic Investigations of The Missing
The revised Statement on Forensic Inves-
tigations of The Missing was adopted as
WMA policy. (p. 180)
Standardisation in Medical Practice and Pa-
tient Safety
The Resolution on Standardisation in Med-
ical Practice and Patient Safety was adopt-
ed. (p. 181)
Criminalisation of Medical Practice
The Resolution on Criminalisation of Med-
ical Practice was adopted. (p. 178)
Right to Rehabilitation of Victims of Torture
The Statement on the Right to Rehabili-
tation of Victims of Torture was adopted.
(p. 182)
Variations of Human Sexuality
The Statement on Variations of Human
Sexuality was introduced and it was pro-
posed that the word ‘natural’ should be
included in the title to be consistent with
the rest of the document. Several speakers
opposed this suggestion, but the proposal
was accepted for the document to be called
‘Natural Variations of Human Sexuality’.
It was then proposed by the Russian Medi-
cal Association that the document should
be sent back for further discussion and
comment. This led to a passionate debate
with speakers on both sides. The Russian
proposal received support from the Ugan-
174
WMA News
da delegation. But Prof. Nathanson argued
that this was an emergency. In at least 50
countries people were being criminalised,
discriminated against and in some places
imprisoned, and threatened with execution
because they had a natural normal varia-
tion of human sexuality. She added: ‘It is
completely unacceptable because this is
being legitimised by bad medicine and
what we are trying to condemn here is
bad medicine, medicine which is trying to
force a change on people when they are in
fact entirely expressing a natural or normal
variation of human sexuality.’ Dr. Lazarus
(American Medical Association) said it
was important that the WMA voted on
this issue today because they were deal-
ing with an opportunity for homosexuals
to live a decent life. He was supported by
delegates from Canada and South Af-
rica. Dr. Torunn Janbu (Norway) said the
WMA should have adopted such a State-
ment years ago. The motion to refer the
Statement back to NMAs for further con-
sideration was defeated. It was then pro-
posed that the word ‘normal’ should be put
back into the document, but on a vote this
was defeated. The Statement, as retitled
‘Natural Variations of Human Sexuality’,
was adopted as WMA policy. (p. 177)
Human Papillomavirus Vaccination
The proposed Statement on Human Papil-
lomavirus Vaccination was adopted. (p. 183)
Brazilian Medical Association
The Resolution in Support of the Brazilian
Medical Association was adopted. (p. 177)
Health Care in Syria
The emergency Resolution on the Health-
care Situation in Syria was adopted. (p. 181)
Prohibition of Chemical Weapons
The Resolution on the Prohibition of
Chemical Weapons was adopted. (p. 178)
Fungal Disease and Management
The Statement on Fungal Disease and
Management was adopted. (p. 179)
Financial Statement and Budget
The Treasurer, Dr. Frank-Ulrich Mont-
gomery, introduced the audited financial
statement for 2012, and explained the de-
tails to the Assembly. He thanked the Sec-
retary General for exercising very efficient
cost control, a risk-free investment policy
and a thrifty use of the budget. The finan-
cial statement was adopted. He then talked
about the budget plans for 2014 which were
approved.
Durban Assembly 2014
The Assembly agreed that at the next Gen-
eral Assembly in Durban, South Africa the
theme of the scientific session would be
‘Universal Access to Health Care after Mil-
lennium Development Goals’.
Future Meetings
It was agreed that the venue for the 2016
General Assembly be Taipei,Taiwan.
Membership
Applications for membership from the
Medical Chamber of Montenegro, the Or-
dre National des Médecins du Cameroun,
the Sudanese Medical Association and the
Federazione Nazionale degli Ordini dei
Medici Chirurghi e degli Odontoiatri, It-
aly were agreed. It was also agreed that the
Hungarian Medical Chamber be accepted
as a member, replacing the Association of
Hungarian Medical Societies.
Presidency
Dr. Haikerwal updated the Assembly on
the situation relating to Dr. Ketan Desai,
whose inauguration as President was sus-
pended in 2010 when he was unable to at-
tend the Assembly in Vancouver following
his arrest and imprisonment. The charges
against him had now been withdrawn and
the Indian Medical Association had re-
quested that Dr. Desai be inaugurated as
President. Dr. Haikerwal said Dr. Desai
had been badly maligned by the Indian
court system. The Council of the WMA
were recommending that the suspension
be lifted and that further consideration be
given to the timing of Dr. Desai’s Presi-
dency at the Council meeting in Tokyo
in April 2014 to be approved by the As-
sembly in Durban in October 2014. The
Assembly agreed to lift the suspension on
Dr.  Desai’s inauguration. A debate then
took place on when a decision should be
taken about the timing of Dr. Desai’s inau-
guration. Dr. Ajay Kumar (Indian Medical
Association) explained the background to
Dr. Desai’s imprisonment and said it was
up to the Assembly to decide when his in-
auguration should take place. Dr. Mzukisi
Grootboom (South Africa Medical As-
sociation) said that a decision about when
Dr. Desai should take up the Presidency
should be decided straight away to send
a strong message to the Indian Govern-
ment. He proposed that there be no elec-
tion for President held at the 2014 Assem-
bly for the 2015 term and that Dr. Desai
be inaugurated as President in 2015. But
Dr. Lazarus said that this was a compli-
cated matter and should be discussed at
the meeting in Tokyo in April. A motion
to discuss the matter immediately was de-
feated and the Assembly agreed to defer
the matter for further consideration until
the Council meeting in Tokyo in 2014.
Report of Associate Members Meeting
Dr. Thorsten Hornung, Past Chair of the
Junior Doctors Network, introduced the
JDN’s policy paper on Physicians Well-
being. He said JDN members from all
over the world had shared their experi-
ences and the data was shocking. He gave
two examples – there were at least 40 per
cent more suicides among physicians com-
175
WMA News
pared to the general population and one in
eight physicians had admitted relying on
alcohol or drugs for stress relief. He said
the medical profession needed to practice
what it preached. In many places physi-
cians experienced extreme working hours
in excess of 100 hours per week, often with
a lack of support structures, bullying and
harassment. ‘Many times we are taught
to deny our own needs and weaknesses,
sadly illustrated by physicians having late
stage psychiatric disease when finally seek-
ing help’, he said. The JDN presented this
paper hoping to collaborate with NMAs
worldwide to make this an important piece
in the WMA’s mission of endeavouring to
achieve the highest international standards
in healthcare for all people in the world.
The Assembly decided to refer the paper to
the Council for consideration.
Health Care in Danger
Dr. Bruce Eshaya-Chauvin, medical ad-
viser on the Health Care in Danger proj-
ect of the International Committee of the
Red Cross, gave a presentation following
the recent Memorandum of Understand-
ing between the WMA and the ICRC. He
said that medical ethics would constitute a
major area of co-operation between the two
organisations. The Health Care in Danger
project encouraged initiatives with NMAs.
He said that violence against patients and
health care workers was one of the most
crucial yet overlooked humanitarian issues
today.He presented data about the numbers
of health care providers and facilities affect-
ed by violent incidents and updated the As-
sembly on the progress of the Health Care
in Danger project. The ICRC alone would
not be able to solve the problem. It would
require global co-operation.
Plain Packaging
Dr. Andrew Pesce (Australian Medical As-
sociation) updated the meeting about the
legal situation relating to the plain ciga-
rette packaging legislation in his country.
The tobacco industry had challenged the
legislation but the courts had found in the
Government’s favour. This should encour-
age politicians not to be too intimidated by
threats of legal action. Complaints had also
been made to the World Trade Organisa-
tion. He also reported on the roll out phase
of introducing the new plain packs. Re-
search had shown there was a measurable
lowering of the appeal of smoking and an
increase in the urgency among smokers to
give up smoking. He said that all NMAs
should increase their efforts to introduce
plain packaging.
Turkey
Prof. Dr. Gülriz Erisgen, Vice President
of the Turkish Medical Association, spoke
about threats to the medical profession in
Turkey. These followed the peaceful dem-
onstrations in Turkey earlier in the year
when extreme violence was used by the
police against legitimate demonstrators.
During this period the Turkish Medical
Association had regularly collected infor-
mation from physicians about the num-
bers of wounded and fatalities. They had
also surveyed injuries caused by the police
use of chemical agents, tear gas, rubber
bullets and water cannons. The Ministry
of Health had now started an investiga-
tion into the Medical Association and
the Chamber of Medicine, asking for the
names of volunteer physicians during the
demonstrations and the names of the in-
jured demonstrators. She said it was im-
possible to give such information. She
thanked the WMA for its support during
this difficult period.
Open Session
During the ‘open session’, held to give del-
egates an opportunity to present to the As-
sembly any profession-specific problem,
policy or project that they believed the
WMA should know about or help address,
delegates from America, Romania, Bahrain
and Nigeria spoke about activities in their
countries. Dr. Ardis Hoven (American
Medical Association) said her Association
had recently undertaken a project to iden-
tify the factors that influenced physicians’
professional satisfaction. This was of in-
creasing importance as health reforms were
changing the practice of medicine. Early
research results suggested that the factors
contributing to physicians’ dissatisfaction
could serve as an early warning to deeper
quality problems developing in the health-
care system. A common theme was physi-
cians describing stress when they saw barri-
ers preventing them from providing quality
care. Solving these problems would be good
for both patients and physicians. Specific
concerns that had been identified were
how electronic record technology interfered
with face to face discussions with patients,
spending too much time on clerical work,
excessive productivity quotas and limita-
tion on the time spent with patients. This
was especially true of primary care physi-
cians. Researchers reported that physicians
reported being more satisfied when their
practice gave them more autonomy, with
the ability to employ more staff members
to take care of clerical work. By identifying
factors that positively influenced physicians’
satisfaction, the AMA was committed to
supporting physicians and also improving
patient satisfaction as well.
Council
A final meeting of the Council was held to
discuss business arising from the Assembly.
It was agreed that the paper from the Junior
Doctors Network on physicians’ well-being
should be circulated to NMAs before being
considered by the Socio-Medical Affairs
Committee.
It was also agreed that the Executive Com-
mittee should consider whether a policy
paper should be developed on weapons of
mass destruction, as suggested by a delegate
from the Bahrain Medical Society.
176
WMA General Assembly Fortaleza, Brazil, October 2013
WMA News
177
WMA Statement on Natural
Variations of Human Sexuality
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
Preamble 
Healthcare professionals encounter many aspects of human diver-
sity when providing care, including different variations of human
sexuality.
A large body of scientific research indicates that homosexuality is a
natural variation of human sexuality without any intrinsically harm-
ful health effects.
As a consequence homosexuality was removed from the American
Psychiatric Association’s official diagnostic manual in 1973. The
World Health Organisation (WHO) removed it from the ICD in
1990 following a similar process of scientific review.The Pan Amer-
ican Health Organization (WHO) states: “In none of its individual
manifestations does homosexuality constitute a disorder or an illness, and
therefore it requires no cure.”
Direct and indirect discrimination, stigmatisation, peer rejection,
and bullying continue to have a serious impact upon the psy-
chological and physical health of people with a homosexual or
bisexual orientation.  These negative experiences lead to higher
prevalence rates of depression, anxiety disorders, substance mis-
use, and suicidal ideations and attempts. The suicide rate among
adolescents and young adults with a homosexual or bisexual ori-
entation is, consequently, three times higher than that of their
peers.
This can be exacerbated by so-called “conversion” or “reparative”
procedures, which claim to be able to convert homosexuality into
asexual or heterosexual behaviour and give the impression that ho-
mosexuality is a disease.These methods have been rejected by many
professional organisations due to a lack of evidence of their effec-
tiveness. They have no medical indication and represent a serious
threat to the health and human rights of those so treated.
Recommendations
The WMA strongly asserts that homosexuality does not represent
a disease, but rather a natural variation within the range of human
sexuality.
The WMA condemns all forms of stigmatisation, criminalisation
and discrimination of people based on their sexual orientation.
The WMA calls upon all physicians to classify physical and psy-
chological diseases on the basis of clinically relevant symptoms ac-
cording to ICD-10 criteria regardless of sexual orientation, and to
provide therapy in accordance with internationally recognised treat-
ments and protocols.
The WMA asserts that psychiatric or psychotherapeutic approaches
to treatment must not focus upon homosexuality itself, but rather
upon conflicts, which arise between homosexuality, and religious,
social and internalised norms and prejudices.
The WMA condemns so-called “conversion” or “reparative” meth-
ods. These constitute violations of human rights and are unjustifi-
able practices that should be denounced and subject to sanctions
and penalties. It is unethical for physicians to participate during any
step of such procedures.
WMA Resolution in Support of
the Brazilian Medical Association
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
There are credible reports that the Brazilian Government pro-
gram “Mais Médicos” to create more medical schools, extend
the duration of the medical course, compulsorily place last years
medical students to work in public services and attract foreign
physicians to work in remote areas of the country and in the poor-
est outskirts of big cities, was proposed without the appropriate
consultation to the medical community and medical schools, and
departs from a wrong diagnosis about the causes of the insuf-
ficient health care provided to the Brazilian population. The pro-
gram as proposed bypass systems established to verify physicians’
credentials, medical competence and language skills in order to
protect patients.
The World Medical Association is concerned that patients are put at
risk by unregulated medical license,inadequate medical competence
and potential misunderstanding of patient communication and of
drugs and medical supplies labels.
Therefore, the WMA:
• Condemns any policy and practice that disrupt the accepted stan-
dards of medical credentialing and medical care;
• Calls upon the Brazilian government to work with the medical
community and medical schools on all matters related to medical
WMA News
178
education, physician certification and the practice of medicine,
and to respect the role of the Brazilian Medical Association on
behalf of the Brazilian physicians and population; 
• Urges, as a matter of utmost concern, that the Brazilian gov-
ernment respect the WMA International Code of Medical
Ethics that guides the medical practice of physicians all over
the world.
WMA Resolution on
the Prohibition of Chemical
Weapons
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
Preamble
It has been recognised for centuries that certain chemical agents
can affect consciousness, or other factors influencing the ability of
an individual to take part in fighting,predominantly during warfare. 
More recently some agents have been used to temporarily disable
participants in civil unrest, protests or riots.  In warfare such agents
have, historically, had a significant morbidity and mortality and in-
cluded nerve gases and related agents.
Despite widespread condemnation such weapons were extensively
used in the early 20th
century. A global movement to outlaw the use
of such weapons led to the development of the Chemical Weapons
Convention (CWC), which entered into force in 1997 having been
opened to signature in 1993.  Currently only six countries have not
ratified or acceded to the CWC.
The production, stockpiling and use of CW is prohibited.  Despite
this, such weapons have been used by state forces and by non-state
actors in a number of countries. By their nature such weapons are
indiscriminate.  This use has led to deaths, injuries and human suf-
fering in those countries.
Chemical agents used in policing actions, including by the military
acting in a policing role, are allowed under the CWC.  There is
a significant international dialogue underway on the definition of
such agents and the situations in which they can be used. It should
be noted that the CWC appears to assume such agents will not
be lethal, but the use of any agent might have fatal consequences. 
Those using them, or authorising their use, must seek to ensure that
they are not used in a manner which risks death or serious injury to
targeted persons.
Recommendations
 The WMA notes that the development,production,stockpiling and
use of Chemical Weapons is banned under the CWC, and that use
of such weapons is regarded by some to be a crime against humanity,
regardless of whether the target populations are civilian or military.
The WMA urges all relevant parties to make active efforts to abide
by the CWC ban on the development, production, stockpiling and
use of Chemical Weapons.
The WMA urges support from all states party to the CWC for the
safe destruction of all stockpiles of Chemical weapons.
The WMA supports UN initiatives to identify anyone who is re-
sponsible for the use of Chemical Weapons and to bring them to
justice.
The WMA urges states using chemical agents in riot control and
related situations to carefully consider and minimise the risks and
to, wherever possible, refrain from such use.  Any use must follow
the establishment of the necessary procedures to reduce the risk of
death or serious injury. They should not be used in a manner, which
deliberately increases the risk of injury,harm or death to their targets.
WMA Resolution on
Criminalisation of Medical
Practice
Adopted as a Council Reolution by the 194th
WMA Council Session, Bali,
April 2013 and adopted by the 64th
 WMA General Assembly, Fortaleza,
Brazil, October 2013
Preamble
Doctors who commit criminal acts which are not part of patient
care must remain as liable to sanctions as all other members of soci-
ety. Serious abuses of medical practice must be subject to sanctions,
usually through professional regulatory processes.
Numerous attempts are made by governments to control physicians’
practice of medicine at local,regional and national levels worldwide. 
Physicians have seen attempts to:
• Prevent medically indicated procedures;
• Mandate medical procedures that are not indicated; and
• Mandate certain drug prescribing practices.
WMA News
179
Criminal penalties have been imposed on physicians for various
aspects of medical practice, including medical errors, despite the
availability of adequate non-criminal redress. Criminalizing medi-
cal decision making is a disservice to patients.
In times of war and civil strife, there have also been attempts to
criminalize compassionate medical care to those injured as a result
of these conflicts.
Recommendations
Therefore, the WMA recommends that its members:
1. Oppose government intrusions into the practice of medicine
and in healthcare decision making, including the government’s
ability to define appropriate medical practice through imposi-
tion of criminal penalties.
2. Oppose criminalizing medical judgment.
3. Oppose criminalizing healthcare decisions, including physician
variance from guidelines and standards.
4. Oppose criminalizing medical care provided to patients injured
in civil conflicts.
5. Implement action plans to alert opinion leaders, elected officials
and the media about the detrimental effects on healthcare that
result from criminalizing healthcare decision making.
6. Support the principles set forth in the WMA’s Declaration of
Madrid on Professional Autonomy and Self-Regulation.
7. Support the guidance set forth in the WMA’s Regulations in
Times of Armed Conflict and Other Situations of Violence.
WMA Statement
on the United Nations
Resolution for a Moratorium
on the Use of the Death
Penalty
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
Preamble
The WMA Resolution on Physician Participation in Capital Pun-
ishment states that it is unethical for physicians to take part in
capital punishment, and the WMA Declaration of Geneva obliges
physicians to maintain the utmost respect for human life.
The WMA acknowledges that the views prevalent in the countries
of some of its members prevent all members unconditionally oppos-
ing the death penalty.
The WMA therefore supports the suspension of the use of the death
penalty through a global moratorium. 
The WMA has long recognized that it cannot hold its national
medical association members responsible for the actions and poli-
cies of their respective governments.
Recommandations
The World Medical Association supports United Nations General
Assembly Resolution 65/206 calling for a moratorium on the use of
the death penalty.
WMA Statement on Fungal
Disease Diagnosis and
Management
Adopted by the 64th
 WMA General Assembly, Fortaleza, Brazil, October
2013
Annual WHO Global Burden of Disease estimates recognize
that fungal diseases account for a significant proportion of health
problems worldwide.  These include cutaneous fungal infections
which affect up to a billion persons and vulvovaginal candidiasis
which affects tens of millions of women, often multiple times an-
nually. 
Even more serious are invasive and chronic fungal diseases that lead
to  estimated annual morbidity rates that are similar to those caused
by commonly recognized global health concerns such as malaria and
tuberculosis. In addition to death, these fungal diseases commonly
lead to chronic ill health, including blindness with keratitis,  respi-
ratory distress with allergic bronchopulmonary aspergillosis (ABPA),
severe asthma with fungal sensitisation (SAFS) and chronic pulmu-
nary aspergillosis (CPA),weight loss and nutritional deficiency with
oesophageal candidiasis and CPA,and inability to engage in healthy
sexual activity with vulvovaginal candidiasis.
Serious fungal diseases are often opportunistic, occurring as a con-
sequence of other conditions that suppress the immune system, such
as asthma, AIDS, cancer, post-transplant immunosuppressive drugs
and corticosteroid therapies. Some occur in critically ill patients.
WMA News
180
Despite the fact that many fungal diseases can be treated relatively
simply,in many cases,these diseases go untreated. Fungal infections
alone are often not distinctive enough to allow a clinical diagnosis,
and as cultures are frequently falsely negative, missed diagnosis is
common. In addition, a relatively narrow diagnostic window to cure
the patient is frequently missed, resulting in prolonged expensive
hospital stays, often with a fatal outcome.  Despite the existence
of effective medicine to treat fungal infections, these are often not
available when and where they are needed.
Statement
The WMA stresses the need to support the diagnosis and man-
agement of fungal diseases and urges national governments to
ensure that both diagnostic tests and antifungal therapies are
available for their populations. Depending on the prevalence of
fungal diseases and their underlying conditions, specific antigen
testing or microscopy and culture are essential. These tests, and
personnel trained to administer and interpret the tests, should
be available in all countries where systemic fungal infections oc-
cur.  This will likely include developing at least one diagnostic
centre of excellence with a sufficient staff of trained diagnostic
personnel. Monitoring for antifungal toxicities should be avail-
able. 
Physicians will be the first point of contact for most patients with a
fungal infection and should be sufficiently educated about the topic
in order to ensure an effective diagnostic approach. 
The WMA encourages its members to undertake and support epi-
demiologic studies on the burden of fungal disease in their country
and to inform the national government of the results.
WMA Statement on Forensic
Investigations of the Missing
Adopted by the 54th
 WMA General Assembly, Helsinki, Finland, Sep-
tember 2003 and amended by the 64th
 WMA General Assembly, For-
taleza, Brazil, October 2013
Preamble
Over the last three decades, forensic investigations into the where-
abouts and fate of people killed and missing as a result of armed
conflict, other situations of violence and catastrophes, have made an
important contribution to humanitarian action on behalf of victims,
including [the deceased and] bereaved families.  Forensic investiga-
tions have also helped in achieving justice and reparations for vic-
tims.
In 2003 the International Conference on The Missing and their
Families, organized by the International Committee of the Red
Cross (ICRC), adopted a set of recommendations to help prevent
people going missing, and resolve the cases of those already miss-
ing, as a result of armed conflicts and other situations of violence. 
The recommendations include ethical, scientific and legal principles
that must apply to forensic investigations in the search, recovery,
management and identification of human remains.These principles
have since been further developed by the ICRC›s forensic services
and they provide a framework for humanitarian forensic action in
situations of armed conflicts, other situations of violence and catas-
trophes1
. The principles also ensure the proper and dignified man-
agement and identification of the dead, and help provide answers to
the bereaved.
National Medical Associations have a role in promoting these
principles and encouraging compliance with them,  and for en-
suring the highest possible ethical, scientific and legal standards
in forensic investigations aimed at addressing the humanitarian
consequences of armed conflicts, other situations of violence and
catastrophes.
In many countries NMAs will not have a role in certifying the qual-
ifications and experience of forensic medical practitioners. NMAs
should draw the attention of practitioners to the best practice
guidelines produced by the ICRC,the United Nations and Interpol,
and recommend or, where possible, require compliance with those
standards.
Recommendations
The WMA calls upon all NMAs to help ensure that,when its mem-
bers take part in forensic investigations for humanitarian and hu-
man rights purposes, such investigations are established with a clear
mandate based upon the highest ethical, scientific and legal stan-
dards,and conform with the principles and practice of humanitarian
forensic action developed by the ICRC.
The WMA calls upon NMAs to develop expertise in the principles
collated by the different authorities on forensic investigations for
1 The ICRC defines catastrophes as disasters beyond expectations. See: M.Tid-
ball-Binz, Managing the dead in catastrophes: guiding principles and practical
recommendations for first responders.International review of the Red Cross,Vol
89 Number 866 June 2007 p.p. 421-442
WMA News
181
humanitarian and human rights purposes, including those devel-
oped by the ICRC to prevent new cases and resolve those of exist-
ing missing persons, and to assist their members in applying these
principles to forensic investigations worldwide.
The WMA calls upon NMAs to disseminate the principles that
should apply to such investigations, including those developed
by the ICRC, and to attempt to ensure that physicians refuse to
take part in investigations that are ethically or otherwise unac-
ceptable.
The WMA calls upon NMAs to help ensure compliance by forensic
medical practitioners with the principles enshrined in international
humanitarian law for the dignified and proper management, docu-
mentation and identification of the dead, and, where possible, pro-
viding answers to the bereaved.
The WMA invites NMAs to be mindful of academic qualifications
and ethical understanding, ensuring that forensic doctors practice
with competence and independence.
WMA Council Resolution
on Standardisation
in Medical Practice and
Patient Safety
Adopted as a Council Resolution by the 194th
 WMA Council Session,
Bali, Indonesia, April 2013 and acopted by the 64th
WMA General As-
sembly, Fortaleza, Brazil, October 2013 
Ensuring patient safety and quality of care is at the core of medical
practice. For patients, a high level of performance can be a matter of
life or death. Therefore, guidance and standardisation in healthcare
must be based on solid medical evidence and has to take ethical
considerations into account.
Currently, trends in the European Union can be observed to
introduce standards in clinical, medical care developed by non-
medical standardisation bodies, which neither have the neces-
sary professional ethical and technical competencies nor a public
mandate.
The WMA has major concerns about such tendencies which are
likely to reduce the quality of care offered, and calls upon govern-
ments and other institutions not to leave standardisation of medical
care up to non-medical self selected bodies.
WMA Resolution
on the Healthcare Situation
in Syria
Adopted by the 64th
  General Assembly, Fortaleza, Brazil, October
2013
Preamble
During wars and armed conflicts, hospitals and other medical fa-
cilities have often been attacked and misused and patients and
medical personnel have been killed or wounded. Such attacks are
a violation of the Geneva Conventions (1949), Additional Pro-
tocols to the Geneva Conventions (1977) and WMA policies, in
particular, the WMA Statement on the Protection and Integrity
of Medical Personnel in Armed Conflicts and Other Situations
of Violence (Montevideo 2011) as well as WMA Regulations
in Times of Armed Conflicts and Other Situations of Violence
(Bangkok 2012).
The World Medical Association (WMA) has been active in con-
demning documented attacks on medical personnel and facilities in
armed conflicts, including civil wars.
The Geneva Conventions and their Additional Protocols are de-
signed to protect medical personnel, medical facilities and their pa-
tients in international and non-international armed conflicts.
The parties on both sides of the conflict have legal and moral duties
not to interfere with medical care for wounded or sick combatants
and civilians, and to not attack, threaten or impede medical func-
tions. Physicians and other health care personnel must act as and be
considered neutral and must not be prevented from fulfilling their
duties.
Recommendations
• The WMA calls upon all parties in the Syrian conflict to ensure
the safety of healthcare personnel and their patients, as well as
medical facilities and medical transport.
• The WMA calls upon its members to approach local governments
in order to facilitate international cooperation in the United Na-
tions, the European Union or other international body with the
aim of ensuring the safe provision of health care to the Syrian
people.
WMA News
182
WMA News
WMA Statement on the Right
of Rehabilitation of Victims
of Torture
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
Preamble
The World Medical Association notes with grave concern the con-
tinued use of torture in many countries throughout the world.
The WMA reaffirms its total condemnation of all form of tor-
ture, and other cruel, inhuman or degrading treatment or pun-
ishment, as defined by the UN Convention Against Torture
(CAT, 1984).
Torture is one of the gravest violations of international human
rights law and has devastating consequences for victims, their
families and society as a whole.
Torture causes severe physical and mental injuries and is a crime
absolutely prohibited under international law.
The WMA reaffirms its policies adopted previously, namely:
• The Declaration of Tokyo laying down Guidelines for Physicians
Concerning Torture and other Cruel, Inhuman or Degrading
Treatment or Punishment in Relation to Detention and Impris-
onment  (1975)
• The Declaration of Hamburg concerning Support for Medical
Doctors Refusing to Participate in, or to Condone, the Use of
Torture or Other Forms of Cruel, Inhuman or Degrading Treat-
ment (1997)
• The Resolution on the Responsibility of Physicians in the Docu-
mentation and Denunciation of Acts of Torture or Cruel or Inhu-
man or Degrading Treatment (2003).
The medical evaluation is an essential factor in pursuing the docu-
mentation of torture and the reparation of victims of torture. Phy-
sicians have a critical role to play in gathering information about
torture, documenting evidence of torture for legal purposes, as well
as supporting and rehabilitating victims.
The WMA recognizes the adoption, in December 2012, by the UN
Committee Against Torture of the General Comment on the Im-
plementation of article 14 of Convention against Torture relating to
the right to reparation of victims of torture.
The General Comment outlines the right of rehabilitation as an
obligation on States and specifies the scope of these services. The
WMA welcomes in particular:
• The obligation of State parties to adopt a “long-term and in-
tegrated approach and ensure that specialized services for the
victim of torture or ill treatment are available, appropriate and
promptly accessible” (paragraph 13), without making access to
these services dependent on the victim pursuing judicial rem-
edies.
• The recognition of the right of victims to choose a rehabilitation
service provider, be it a State institution, or a non-State service
provider, which is funded by the State.
• The recognition that State parties should provide torture victims
with access to rehabilitation programs as soon as possible follow-
ing an assessment by qualified independent healthcare profes-
sionals.
• The references in paragraph 18 to measures aimed at protecting
health and legal professionals who assist torture victims, develop-
ing specific training on the Istanbul Protocol for health profes-
sionals, and promoting the observance of international standards
and codes of conduct by public servants, including medical, psy-
chological and social service personnel. 
Recommendations
The WMA emphasizes the vital function of reparation for vic-
tims of torture and their families in rebuilding their lives and
achieve redress and the important role of physicians in rehabili-
tation.
The WMA encourages its member associations to work with rel-
evant agencies – governmental and non-governmental – acting for
the reparation of victims of torture, in particular in the areas of doc-
umentation and rehabilitation, as well as prevention.
The WMA encourages its members to support agencies that are
under threat of – or subjected to – reprisals from state parties due
to their involvement in the documentation of torture, rehabilitation
and reparation of torture victims.
The WMA calls on its members to use their medical experience
to support torture victims in accordance with article 14 of the UN
Convention against Torture.
The WMA calls on its member associations to support and facili-
tate data collection at the national level in order to monitor the
implementation of the State’s obligation to provide rehabilitation
services.
183
WMA News
WMA Statement on Human
Papillomavirus Vaccination
Adopted by the 64th
 General Assembly, Fortaleza, Brazil, October 2013
Preamble
Human papillomavirus (HPV) vaccination presents a unique and
valuable opportunity for physicians to substantially prevent mor-
bidity and mortality from certain cancers in all populations, and to
improve maternal health. The HPV vaccine therefore merits con-
sideration by the World Medical Association (WMA) separately
from other vaccines.
HPV is a sexually transmitted virus and is so common that most
sexually active adults become infected at some point in their lives.
Most infections are asymptomatic and resolve without medical in-
tervention. However, some of the 40 types of HPV can cause cervi-
cal cancer. HPV is the cause of nearly 100% of cervical cancer cases
and may also cause cancer of the vagina, vulva, anus, penis and the
head and neck. Cervical cancer accounts for more than 10% of all
female cancers, and the majority of cervical cancer deaths are in
developing countries.
Vaccines can protect against infection by the most common HPV
types and afford protection against cancer. The U.S. Advisory Com-
mittee on Immunization Practices recommends HPV vaccination for
both females and males starting at age 11 years up to age 26 years.
Benefits of vaccinating young men include protection against genital
warts and cancer in addition to preventing transmission of HPV to
sexual partners. The additional protection afforded by the quadriva-
lent vaccine against genital warts as well as cervical and other cancers
should be taken into consideration when developing HPV vaccina-
tion programmes. The HPV vaccines are effective; post-marketing
studies have shown decreases in HPV prevalence and HPV related
disorders such as genital warts and abnormal cervical cytology. Stud-
ies concerning the safety of HPV vaccines have been reassuring. 
These vaccines should be made widely available and should be pro-
moted by physicians as a matter of individual patient wellbeing and
public health. 
Recommendations
The WMA urges physicians to educate themselves and their pa-
tients about HPV and associated diseases, HPV vaccination and
routine cervical cancer screening; and encourages the development
and funding of programs to make HPV vaccine available and to
provide cervical cancer screening in countries without organized
cervical cancer screening programs.
National medical associations (NMAs) are encouraged to carry out
intensive education of and advocacy efforts toward their members
to:
• Improve awareness and understanding of HPV and associated
diseases;
• Understand the availability and efficacy of HPV vaccines;
• Understand the desirability of including HPV vaccines in nation-
al immunization programs;
• Understand the need for routine cervical cancer screening; and
• Integrate HPV cancer prevention methods, early detection and
screening, diagnosis, treatment and palliative care into existing
continuing professional development programs and pre-service
training. Such training will leverage existing support for HPV
programs and help in capacity building and quality assurance ef-
forts.
NMAs are also encouraged to:
• Integrate HPV vaccination for all adolescents and routine cervi-
cal cancer screening for young women into all appropriate health
care settings and visits;
• Support the availability of the HPV vaccine and routine cervi-
cal cancer screening for appropriate populations that benefit most
from preventive measures, including but not limited to at-risk
patients such as low-income, disadvantaged and populations that
are not yet sexually active;
• Recommend HPV vaccination for all appropriate populations;
• Promote member advocacy for HPV prevention, care and treat-
ment; and
• Create a network of physicians and practitioners who are will-
ing and able to mentor and support one another and establish
linkages to existing HPV vaccine and cancer prevention net-
works.
WMA Resolution on Women’s
Rights to Health Care and How
That Relates to the Prevention of
Mother-to-Child HIV Infection
Adopted by the 53rd
  WMA General Assembly, Washington, DC,
USA, October 2002 and amended by the 64th
WMA General Assembly,
Fortaleza, Brazil, October 2013 
184
WMA News
Preamble
In many parts of the world the prevalence of HIV infection con-
tinues to increase. One of the Millennium Development Goals
(MDG 6), specifically targets combating HIV/AIDS, malaria and
other diseases, with 2015 being its target year to halt HIV/AIDS
infection and to begin reversing the spread of HIV/AIDS. In ad-
dition, it was hoped that by 2010 universal access to treatment
for HIV/AIDS for all those requiring it would be achieved. A
December 2012 UN resolution declared that countries must de-
velop programmes for Universal Health Access after 2015 when
the MDGs end.
HIV/AIDS is a disease that disproportionately affects people in
their reproductive years although today, due to better management
of the condition, there are also many older people who are infected.
In addition, many who were infected as infants are now reaching
reproductive maturity.
In developed countries men who have sex with men and injection
drug users constitute significant risk groups for contracting HIV.
In many developing countries, women are at risk due to hetero-
sexual contact with HIV infected partners. In 2011 approximately
58 percent of people living with HIV in sub-Saharan Africa were
women,equating to about 13.6 million women living with HIV and
AIDS, compared to about 9.9 million men(UNAIDS  ‘Global Fact
Sheet 2012: World AIDS Day 2012).
In the absence of HIV, maternal mortality worldwide would be sig-
nificantly (20% ) lower (Murray et al. Maternal mortality for 181
countries, 1980–2008:  a systematic analysis of progress towards
Millennium Development Goal 5).
HIV infection increases the risk of invasive cervical cancer 2 to 22
fold. Some evidence exists that the use of antiretroviral therapy may
decrease this risk. Hence, the appropriate management of patients
infected with HIV may have a long-term impact on other aspects
of women’s health.
The WMA believes that access to healthcare, including both thera-
peutic and preventative strategies, is a fundamental human right.
This imposes an obligation on government to ensure that these hu-
man rights are fully respected and protected.  Gender inequalities
must be addressed and eradicated.  This should impact every aspect
of healthcare.
The promotion and protection of the reproductive rights of women
are critical to the ultimate success of confronting and resolving the
HIV/AIDS pandemic.
Many of the MDGs address empowering women and promot-
ing their role in society and specifically in healthcare. MDG 5B,
in particular, promotes universal access to reproductive health in-
cluding contraceptive access, reduction in adolescent birth rate,
antenatal care coverage and addressing unmet needs for family
planning.  In addition, MDG 3 which promotes gender equality
and empowers women,  and MDGs 1 and 2 will influence wom-
en’s status in society and therefore their access to healthcare and
health promotion. 
Recommendations
The WMA requests all national member associations to encour-
age their governments to undertake and promote the following
actions: 
• Develop empowerment programs for women of all ages to en-
sure that women are free from discrimination and enjoy uni-
versal and free access to reproductive health education and life
skills training. It is recommended that campaigns be initiated
and activated in the media, including social media and popu-
lar programmes on radio and television in order to eradicate
myths, stigma and stereotypes that might degrade or dehuma-
nise women.  This must include campaigns against genital mu-
tilation and forced adolescent marriages and unwanted preg-
nancies.  In addition, promoting the availability and choice of
contraception for women, without necessarily having to get in-
put from their partners, and promoting the availability of HIV
testing and treatment are essential for reproductive health. It is
also important to provide for the economic  means for the in-
fected populations in terms of prevention, treatment and medi-
cal follow-up.
• Women must have the same access as men, without discrimina-
tion to education, employment, economic independence, infor-
mation about healthcare and health services.
• Laws, policies and practices that facilitate the full recognition
and respect of human rights and the fundamental freedom of
women should be initiated or reviewed and revised where ap-
propriate. It is essential that women are empowered to make de-
cisions regarding their children, their financial status and their
future.
• All governments should develop programmes to provide pro-
phylactic treatment in the form of antiretrovirals to women who
have been raped or sexually assaulted.  Universal and free access
to antiretroviral therapy must also be provided to all HIV infected
women.
• HIV infected women who are pregnant should receive counsel-
ling and access to anti-retroviral prophylaxis or treatment in order
to prevent mother to child transmission of HIV.
185
Declaration of Helsinki
Introduction
“Le mieux est l’ennemi du bien.” (The perfect is
the enemy of the good.)”
The Philosophical Dictionary attributes this
familiar quote to the French philosopher
Voltaire, and more specifically to his poem
La Bequeule which begins: “Dans ses écrits,
un sage Italien, it que le mieux est l›ennemi du
bien“ (which translates as: ‘In his writings, a
wise Italian says that the best is the enemy
of the good’). The translation of “mieux”
as ‘best’ or ‘perfect’ is a matter of minor
translational dispute, but this has become a
common aphorism, so common in fact that
inserting “the perfect is the enemy of the
good”into the Google search engine returns
71,800,000 results (in 0.34 seconds). Like
all pieces of good advice, the point being
made is clear: sometimes it is preferable to
make things better rather than striving for
perfection. Presumably the thinking is part-
ly pragmatic: to achieve perfection may take
more time or resources than are available
and hence the pragmatic solution of achiev-
ing something (rather than nothing) is con-
sidered a wise strategy. It is also likely that
advice about pursuing perfection is an epis-
temic asymptote in that one can constantly
try to seek perfection and can move closer,
but the effort will ultimately fail given that
an accepted definition and understanding
of the perfect is either beyond our knowl-
edge or at least beyond political consensus.
Achieving perfection is hard. The Oxford
English Dictionary defines it as: “In a state
of complete excellence; free from any im-
perfection or defect of quality; that cannot
be improved upon; flawless, faultless”. This
is why debates persist in Olympic scoring,
physical attributes, the cut of a diamond, or
in a written document.
No one is (or should be) arguing that the
Declaration of Helsinki is a perfect docu-
ment. But after five decades, six revisions
and two Notes of Clarification it is an ap-
propriate occasion to look backwards at the
evolution of some of its more controversial
sections and ponder how much further it
still needs to go to get closer to a document
worthy of its status as one of the most au-
thoritative statements on ethical standards
for human research in the world [1].
Among the Most Controversial
Principles: Placebos and
Provision of Care
Placebos and Standard of Care. Few topics
have occupied the attention of regulators,
governments, sponsors, or academic com-
mentators as much as the Declaration’s
efforts to provide principled advice on the
justification for using placebos in biomedi-
cal research. I recall vividly the debates over
this topic in the late 1990s when the US
National Bioethics Advisory Commission
was undertaking work on a report on the
ethics of international clinical trials [2,3].
It was during the course these deliberations,
and subsequent discussions by other groups
such as the Nuffield Council for Bioethics
[4] that sides were taken on the ethical ac-
ceptability of placebos. Stimulated in part
by the published responses to the ACTG-
076 maternal-fetal HIV transmission trials
[5-7], the WMA weighed in on this topic
in the 2000 revision and then in a clarifying
note in 2002 which, arguably, did little to
settle the issues. Indeed, one commentator
has referred to the placebo principle (then
Principle 29) in a prior version of the Dec-
laration as one of the two “most controver-
sial elements of the whole Declaration” (the
other being principle 30 relating to post
study obligations [8].
At stake was whether the ethical and sci-
entific justification for including a placebo
would meet an agreed standard of care,
which itself has been the subject of ongo-
ing deliberation [9]. The choice of whether
a new intervention could be tested against
a placebo (or no treatment) only when no
established effective, no proven, no current
proven, no best available treatment existed
preoccupied much of the debate over the
past decade. Wording changes in Principle
33 such as where “methods” replaces “treat-
ments”, provide some conceptual clarifica-
tion, but any gains in clarity may still be lost
when considering that the Declaration is
translated into the three official languages
of the WMA, presenting certain interpreta-
tion problems [10].
This has had the effect of creating a policy
‘valley of death’, which has been described
as an environment in which policy advice
If Perfect Isn’t Possible, Is The Good “Good Enough?”
Placebos, Post-Trial Provisions and the Politics of Helsinki
Eric M. Meslin
186
Declaration of Helsinki
(including guidelines) may actually im-
pede scientific progress if not presented in
an implementable way [11]. Little progress
was made to traverse what has become a
policy valley of death on this issue; that is
the 2013 draft revision maintains the status
quo with only minor grammatical changes
for terminological consistency, such as re-
placing “treatment” with “intervention” and
deleting “current” as a qualifier for “proven”.
This may be as good as it gets so long as
the Helsinki reflects the considered judg-
ment of the WMA members on the ethics
of placebo controls a position that has not
changed in almost 15 years.
Language notwithstanding, this principle
has been, and one suspects will continue to
be controversial as it relates to the question
on when is it acceptable to design a study
with a placebo (or no treatment). Regret-
tably, the debate has been mired in a set of
epistemic problems including whether the
standard of care is determined locally or
globally. Such issues are further influenced
by the economics of drug development and
pricing. Arguably, one of the objections to
the ACTG-076 trials, namely that it would
be unethical to test a drug regimen that
would be too expensive for implementation
in Low and Middle Income Countries [6],
would carry less weight if the price of medi-
cines can be reduced in those countries.
Given the tremendous progress that has
been made to lower drug prices by many or-
ganizations, as well as innovative approach-
es for negotiating price [12], the way should
be cleared somewhat for continued discus-
sion about the scientific and ethical merit of
using placebos.
Provision of care at the End of a Study.
Slightly less controversial than the placebo
principle is the laudable effort in the Dec-
laration to provide guidance in Principle 34
on the issue of what, if anything, is owed at
the end of a study, to whom, and on whose
shoulders any obligation may rest. Like the
placebo principle, the history of this provi-
sion can be traced back to the debate at the
end of the last century to recognize and try
to encourage implementation of a moral in-
tuition about the ethical obligation to pro-
vide some type of care or treatment to those
who participate in studies and would ben-
efit from continued access to a beneficial
treatment [3]. Unlike the placebo principle,
the controversy about which is focused on
whether one can set firm conditions on
when it should be used at all, the post-trial
provision principle is controversial because
it does not set firm limits on the scope of
the ethical expectations created. Accepting
for the moment that the provision is unique
in that (even if not explicitly stated) it is
on research undertaken in LMICs since no
such provision is found in national guide-
lines for economically developed countries,
it is still a provision that is challenging to
implement consistently. Consider the diffi-
culty in identifying those who still need an
intervention identified as beneficial, given
factors such as symptom improvement,
safety monitoring, or other requirements
for ongoing care. These and other concerns
were partly responsible for the need to
produce a further Note of Clarification in
2004 at the Tokyo meeting of the WMA
reaffirming the need “during the planning
process to identify post trial access by study
participants to prophylactic, diagnostic
and therapeutic procedures identified as
beneficial in the study or access to other
appropriate care” [13]. This provision may
be as good as Helsinki can get so long as
the WMA, like many other organizations,
continues to support the idea that among
the best ways to respect the best interests of
patients involved in studies is by encourag-
ing protocols to include provisions for on-
going care, to empower ethics committees
to review these aspects of protocols, and
for prospective research participants to be
made aware of such provisions during the
consent process. However, it is also likely
that as more collaborative research occurs
involving participants from many different
countries – some of whom will not have
domestic provisions in their own gover-
nance documents that accept this provision
in Helsinki – there will be conflicts about
the best way to satisfy this provision.
The Politics and Ethics
of the Declaration as a
Policy Instrument
One of the great strengths of the Declara-
tion is the impact that its widespread use
has on the policy positions of countries
throughout the world. Many countries who
have not developed their own national eth-
ics guidelines have adopted Helsinki as
their national standard. It is, therefore, first
and foremost, a governance document in-
tended to guide the conduct of domestic
research in a global environment. In this
way it is different from the hundreds of do-
mestic guidelines each of which were writ-
ten to provide substantive direction for the
conduct of research in those countries [14].
In becoming a global document, inevitably
it also has become a political document,
which should come as no surprise as it is
reflects the consensus view of the world’s
medical associations. As such, there is no
denying that among the challenges that this
increasingly popular document faces is the
“politicization” of its content [8]. Five and
half years ago, the Declaration found itself
the object of a political dispute when the
U.S.Food and Drug Administration (FDA)
announced that it would be substituting its
historic reliance on the Declaration as the
standard for judging the ethical acceptabil-
ity of international clinical trials with those
standards adopted by the International
Conference on Harmonization’s (ICH)
Guideline for Good Clinical Practice [15].
Some of us speculated about the possible
reasons that the FDA under then U.S.
President George W. Bush used to justify
this policy maneuver [1]. Just as the plural
of anecdote is not data, neither is it appro-
priate to elevate speculation about political
motives to the level of confirmed intention.
Still one does not have to be a conspiracy
theorist to appreciate the mutual benefits
187
Declaration of Helsinki
of adopting a standard that enjoys consen-
sus among those parties whose interactions
require a common standard or benchmark.
In the case of licensing and marketing new
medicines, there is a decided advantage for
the pharmaceutical industry in the U.S.,
Europe and Japan to abide by the ICH
standard – having developed it jointly – as
contrasted with adopting the Helsinki stan-
dard which was developed by the WMA.
These maneuverings should not, however,
diminish the confidence that the public
might be expected to have in the integrity
of research undertaken in compliance with
Helsinki. The WMA should be congratu-
lated for its efforts to democratize the revi-
sion process by taking many steps to con-
vene working groups and expert panels in
different countries over many months, and
to solicit public comments on the revision
online. The final draft received fewer than
130 comments from around the world but
while this seems an unusually small number
for a document of such importance, the ex-
planation may be found in the lessons from
other efforts to engage the public in policy
making [16–17]. most notably that public
commentary is a labor intensive and some-
times technology dependent activity.
Conclusion
The Declaration of Helsinki is not a per-
fect document and perhaps it can never be.
It has enjoyed a unique status that has im-
proved over time, as each subsequent revi-
sion has attempted to be responsive to new
developments in science and deeper ethical
and policy reflections. No sooner will the
current revision be finalized and dissemi-
nated then the process will start again as
one would expect of a living document in
research ethics.
Disclaimer:This paper is based in part on com-
ments provided at the “Stakeholders Meeting
on the Revision of the Declaration of Helsinki”,
August 26, 2013, Washington, DC.
References
1. Kimmelman J, Weijer C, Meslin EM, The Hel-
sinki Discords: FDA, Ethics, and International
Drug Trials, The Lancet 373(9657): 13-14, Janu-
ary 2009 doi:10.1016/S0140-6736(08)61936-4
2. National Bioethics Advisory Commission.Ethi-
cal and Policy Issues in International Research:
Clinical Trials in Developing Countries (2001).
NBAC. Rockville, MD, http://bioethics.george-
town.edu/nbac/clinical/Vol1.pdf
3. Shapiro HT and Meslin, EM. Ethical Issues in
the Design and Conduct of Clinical Trials in
Developing Countries. New England Journal of
Medicine 2001;345:139-141
4. Nuffield Council on Bioethics. The ethics of re-
search related to healthcare in developing coun-
tries. Nuffield Council (2002). www.nuffieldbio-
ethics.org/research-developing-countries
5. Varmus H, Satcher D, Ethical complexities of
conducting research in developing countries. N
Eng J Med 1997;337: 1003-1005
6. Lurie P, Wolf SM. Unethical trials of interven-
tion to reduce perinatal transmission of the hu-
man immunodeficiency virus. N Eng J Med,
1997;337; 853-855
7. Angell, M. The ethics of clinical research in the
third world. N Eng J Med. 1997; 337: 847-9
8. Ashcroft, RE. The Declaration of Helsinki. In
Emanuel EJ, Grady C, Crouch RA, Lie RK,
Miller FG, Wendler D. eds. The Oxford Textbook
of Clinical Research Ethics. Oxford University
Press (2008): 146.
9. Macklin, R. Double Standards in Medical Re-
search in Developing Countries. Cambridge
University Press, 2004.
10. Carlson RV, van Ginneken NH, Pettigrew LM,
Boyd KM, Webb DJ, The three official lan-
guage versions of the Declaration of Helsinki:
what’s lost in translation? J Med Ethics. 2007
September; 33(9): 545–548. doi:  10.1136/
jme.2006.018168
11. Meslin EM, Blasimme A, Cambon-Thomsen
A, Mapping the Science Policy ‘Valley of Death’
Clinical and Translational Medicine. 2013, 2:14.
DOI: 10.1186/10.1186/2001-1326-2-14
12. Lucchini S, Cisse B, Duran S, de Cenival M,
Comiti C, Gaudry M , Moatti JP Decrease in
Prices of Antiretroviral Drugs for Develop-
ing Countries: from Political “Philanthropy” to
Regulated Markets? http://apps.who.int/medi-
cinedocs/documents/s18253en/s18253en.pdf
13. World Medical Association. Declaration of
Helsinki: Ethical Principles for Medical Re-
search Involving Human Subjects.Tokyo, Japan.
WMA: October 2004 [Online]. http://www.
wma.net/en/40news/20archives/2004/2004_24/
(Accessed October 16, 2013)
14. Office of Human Research Protections. 2013
Edition of the International Compilation of
Human Research Standards. http://www.hhs.
gov/ohrp/international/index.html (Accessed
October 16, 2013)
15. Department of Health and Human Services,
Food and Drug Administration. Human sub-
ject protection; foreign clinical studies not
conducted under an investigational new drug
application. Fed Reg April 28, 2008. 22800-16.
http://www.fda.gov/cber/rules/forclinstud.pdf
(accessed Nov 9, 2008).
16. Meslin EM. When Policy Analysis is Carried
Out in Public: Some Lessons for Bioethics from
NBAC’s Experience. In: James Humber and
Robert Almeder, eds. The Nature and Prospect of
Bioethics: Interdisciplinary Perspectives. Humana
Press: Totowa, NJ. 2003: pp. 87-111.
17. Singer PA, Taylor AD, Daar AS, Upshur REG,
Singh JA, et al. (2007) Grand Challenges in
Global Health: The Ethical, Social and Cultural
Program. PLoS Med 4(9): e265. doi:10.1371/
journal.pmed.0040265
Funding
Support from Grant # 2R25TW006070-05,
Fogarty International Center, NIH; Grant #
UL1RR025761-01, NCATS, NIH. Meslin is
a consultant to the Ethical, Social and Cultural
Program of the Grand Challenges in Global
Health (GCGH) initiative funded by the Bill
& Melinda Gates Foundation.
Eric M. Meslin, Ph.D.
Director, Indiana University
Center for Bioethics
Professor of Bioethics
Associate Dean for Bioethics
Indiana University School of Medicine
Indianapolis, USA 46202
E-mail: emeslin@iu.edu
188
Declaration of Helsinki
Since the first version of the Declara-
tion of Helsinki (DoH) was adopted in
1964, it has been revised nine times and
numerous other bodies have promulgated
ethics guidance documents. During this
same period, scientific research with hu-
man subjects has dramatically increased in
size, scope, and importance. If the DoH
is to continue to play a significant role in
regulating the research enterprise, it must
convincingly convey a coherent, if highly
general, view of the research enterprise
and the basic normative requirements nec-
essary to preserve its integrity and protect
the rights and welfare of participants. In
what follows, I argue that the emphasis in
the DoH on detailed prescriptive require-
ments untethered from general justifica-
tory grounds means that it is particularly
dependent on readers to supply underlying
normative justifications. Without these
normative grounds, its provisions might
appear inconsistent, unfounded, or arbi-
trary.
To make this argument, I provide a read-
ing of several revised passages in the 2013
DoH. This reading draws on a normative
framework that emphasizes a particular
view of the proper division of labor be-
tween research and medical and public
health systems and the threat that biased
or poor quality research poses to those
systems. It also treats various provisions
of the DoH as helping to provide a pub-
lic assurance to stakeholders that the re-
search enterprise functions as a system of
mutually beneficial social cooperation in
which all parties are respected as free and
equal contributors [1]. Although these
commitments are not expressed within
the DoH itself, this reading illustrates
strengths and weakness of the new docu-
ment and highlights areas for improve-
ment.
Integrity of Scientific
Information
The 2013 version of the DoH contains
several changes that significantly expand
the scope of requirements relating to the
registration of research and the disclosure
of findings. For example, the requirement
for trial registration has been expanded
from “every clinical trial” in the 2008 ver-
sion to “every research study involving hu-
man subjects” (par. 35). With this expanded
scope, this requirement now covers a wider
range of research activities. For example,
the 2008 wording would not cover sub-
studies carried out within larger trials, such
as biomarker studies, because these are not
separate clinical trials. Such sub-studies are
covered under the new language because
they are research studies involving human
subjects.
This expanded requirement also highlights
a tension with the DoH. On the one hand,
it claims to explicitly address only physi-
cians. But to the extent that its require-
ments apply to every study involving hu-
man subjects, they would apply to research
covered by non-physicians as well. Limiting
the scope of the provisions to only research
with human subjects that is conducted by
physicians seems arbitrary, at best. More-
over, the requirement that research results
be published has been expanded to include
“publication and dissemination” and this
obligation is now ascribed to sponsors as
well as researchers, authors and editors (par.
36).The language of this paragraph has also
been strengthened from “should” to “must”
in several places, including the obligation to
publish negative and inconclusive findings
and to report conflicts of interest.
These concrete prescriptions assign poten-
tially costly duties to a range of stakeholders
and their requirements are not limited by
disciplinary orientation or by the degree of
risk posed to study participants. It is some-
what surprising, therefore, that the DoH
does not contain an explicit statement of
their normative grounding or justification.
In particular, there have been a number of
proposals recently to titrate the level of re-
search oversight to risk as a way of reign-
ing in what is criticized as costly regulatory
overreach [2, 3]. The only explicit discus-
sion of the “importance” of a “research ob-
jective” in the DoH is to state that it must
outweigh the risks and burdens imposed on
participants (par. 16, 2013). If a study poses
little to no risk to participants, there is no
independent ground stated in the DoH to
justify requiring uniformly high oversight
for it and risker or more burdensome stud-
ies.
The DoH would benefit, therefore, from
an explicit statement that these require-
ments are justified because registration of
studies and comprehensive reporting of all
study data, including negative and incon-
clusive results, are necessary to ensure the
Justification, Coherence and Consistency
of Provisions in the Revised Declaration
of Helsinki
Alex John London
189
Declaration of Helsinki
reliability, relevance, and validity of scien-
tific information. As the DoH states, the
primary purpose of research involving hu-
man subjects is “to understand the causes,
development and effects of diseases and
improve preventive, diagnostic and thera-
peutic interventions (methods, procedures
and treatments)” (par.  6). Reliable, rel-
evant, and valid data are essential to the
ability of the research enterprise to fulfill
this purpose.
In modern health systems and health pol-
icy, many forms of research with human
subjects contribute data on which clini-
cians, patients, researchers, institutions,
policy makers, and others rely in making
decisions that affect the health and wel-
fare of individuals and groups and the al-
location of scarce resources [4]. Because
research data are the bedrock of evidence-
based health systems and social policy, the
quality and reliability of that information
affects the health, welfare, and rights of the
individuals who rely on those health sys-
tems to address their health needs. Even
research that imposes little or no risk to
study participants can generate data that is
biased or of poor quality. Concerns about
the quality of low risk studies have sur-
faced frequently in the context of postmar-
keting research, where decreased oversight
removes incentives and safeguards against
using biased evidence to advance market-
ing objectives, sometimes at the expense of
patient health [5,6]. Similar concerns have
emerged recently in biomarker studies as
well [7,8].
Strengthening registration, publication
and reporting requirements is justified by
their contribution to ensuring the quality
and reliability of research data. Ascribing
obligations for registration, reporting, and
dissemination of study findings to a broad
range of stakeholders is also warranted
because responsibility for ensuring the in-
tegrity of the research enterprise must be
shared by all of the parities that assert some
control over critical aspects of that process.
The WMA may be uncomfortable stating
moral requirements for stakeholders beyond
physicians, but omitting the obligations of
others would either cripple the document’s
ability to provide comprehensive ethical
guidance across the lifecycle of research or
it would lead to unfairly attributing to phy-
sicians responsibilities that vest in and must
be discharged by other parties.
Responsiveness and Benefits
In several places, the 2008 DoH states that
populations in which research is carried out
should stand to benefit from the results of
research. Paragraph 17 of the 2008 ver-
sion reads, “Medical research involving a
disadvantaged or vulnerable population or
community is only justified if the research
is responsive to the health needs and pri-
orities of this population or community and
if there is a reasonable likelihood that this
population or community stands to benefit
from the results of the research.” Paragraph
33 of the 2008 version uses even broader
language, “At the conclusion of the study,
patients entered into the study are entitled
to be informed about the outcome of the
study and to share any benefits that result
from it, for example, access to interventions
identified as beneficial in the study or to
other appropriate care or benefits.”
Although the most direct result of research
is new information and knowledge, re-
search can also produce new interventions,
improved infrastructure, and potentially
lucrative financial rewards. If the core re-
quirement for research in disadvantaged
populations is that those populations ben-
efit from participation, and if there are
myriad benefits that can flow from research,
then critics might wonder why research
should be required to meet the responsive-
ness requirement at all [9].
The current revision of the DoH retains
responsiveness as a requirement and elimi-
nates this ambiguity:
Medical research with a vulnerable group is
only justified if the research is responsive to the
health needs or priorities of this group and the
research cannot be carried out in a non-vul-
nerable group. In addition, this group should
stand to benefit from the knowledge, practices
or interventions that result from the research
(par 20).
Although the responsiveness requirement
will undoubtedly be subject to further criti-
cism for vagueness, this language makes it
clear that the primary consideration in eval-
uating research in vulnerable groups should
be the relationship of the questions being
investigated, and the knowledge that is ex-
pected to be generated, to the health needs
or health priorities of that group.
The current version of the DoH does not
contain a justification for this requirement,
and some changes to the text obscure one
potential justificatory ground. That is, in
the 2008 version, the statement “Medical
progress is based on research that ultimate-
ly must include studies involving human
subjects” is followed immediately by the
claim that “Populations that are underrep-
resented in medical research should be pro-
vided appropriate access to participation
in research,” (par 5, 2008). Although both
claims are retained in the 2013 revision,
the second now appears as an independent
statement (par. 13), eight paragraphs after
the former claim (par. 5). Separating these
claims severs the natural justificatory link
that was at least implied in the previous
version.
The link that is more clearly implied in the
2008 version is that inclusion in research
is necessary for vulnerable groups to share
in medical progress. Excluding vulner-
able groups from research stifles what is,
if not the only, then the most efficient, av-
enue through which their distinctive health
needs can be understood and addressed. If
the fundamental purpose of research with
human subjects is to produce the evidence
necessary to improve standards of care and
190
Declaration of Helsinki
prevention, then exclusion from research
creates or perpetuates evidence gaps. This
means that health systems have fewer effec-
tive interventions for the distinctive health
needs of excluded groups and that patients
from these groups are exposed to elevated
risk when they access those health systems
[10].
Although the DoH is not explicit about the
relationship between the requirements that
have been discussed so far, there is a read-
ing on which they can be seen as playing
a crucial role in the social justification of
research. On this view, the purpose of re-
search is to produce a unique social good,
namely, the information necessary to en-
able health systems to better understand
and address the health needs of the people
they serve [1, 4, 6]. This good is unique,
because unlike other benefits that stake-
holders seek from research participation,
it often cannot be produced in any other
way. Promoting access to research among
underrepresented groups is thus necessary
to promote equity in the capacity of health
systems to meet the needs of the diverse
communities that they serve. The respon-
siveness requirement, and the requirements
relating to registration and publication are
necessary to ensure that when individuals
and groups participate in research, they
have public assurance that they are help-
ing to generate information that is likely to
strengthen and improve the health systems
on which they depend.
This kind of social justification is impor-
tant because it legitimates social and indi-
vidual support for the research enterprise
as a collaborative undertaking [1]. In par-
ticular, medical and public health research
require the support of diverse stakeholders,
from researchers and institutions of scien-
tific advancement, to public and private
sponsors, participants, policy makers, and
the community in whose name research
is often conducted and whose interests
it is supposed to advance. Many of these
parties may contribute to the research en-
deavor for a variety of reasons. Some may
seek profit, career advancement, access to
medical care, prestige, or some mixture of
these and other motives. These parochial
motives alone cannot justify social sup-
port for the research enterprise, since not
all parties seek the same parochial goals,
there are often other means of advancing
these ends, and because pursuit of these
goals can sometimes come at the expense
of other parties.
In contrast, research is often the only way
to produce the evidence base necessary
for health systems to effectively and ef-
ficiently meet the diverse health needs of
the individuals that they serve. Because
community members must rely on medical
and public health services to address their
basic health needs, ensuring equity in their
capacity to fulfill this mission can be seen
as a legitimate focus for social support and
the use of social resources. When there is
credible public assurance that the research
system is designed to advance this goal,
all of the necessary stakeholders can par-
ticipate with the warranted belief that even
if they each contribute in order to pursue
some parochial interest, the system will not
be coopted so as to siphon social support
and social resources simply to advance the
parochial interests of some at the expense
of the others.
I am suggesting that it is useful to view the
provisions discussed so far as helping to
provide a public assurance to stakeholders
that the research enterprise functions as a
system of mutually beneficial social coop-
eration in which all parties are respected
as free and equal contributors [1]. Because
study participants are the most at risk of
having their status as free and equal per-
sons compromised in research participation,
they require special assurance that their
rights and welfare will be respected. Ethi-
cal principles that are traditionally viewed
as forming the moral core of research ethics
(such as informed consent, the minimiza-
tion and justification of risk, and protec-
tions for confidentiality) can then be seen
as special requirements necessary to ensure
proper respect for study participants as free
and equal.
The 2013 DoH contains a new provision
that can be read as trying to ensure that
participant interests are not compromised
through research participation.It holds that,
“Appropriate compensation and treatment
for subjects who are harmed as a result of
participating in research must be ensured”
(par. 15). If the legitimate social purpose of
research is to generate a public good – the
evidence base for effective and equitable
health systems – then compensation for
study-induced harms can be grounded in
reciprocity. The DoH does not specify who
bears this obligation and it would seem un-
reasonable to saddle researchers alone with
it since other stakeholders who contribute
to and benefit from the enterprise are better
situated to effectuate it.
Similarly, the new paragraph 34 holds that,
“In advance of a clinical trial, sponsors, re-
searchers and host country governments
should make provisions for post-trial access
for all participants who still need an inter-
vention identified as beneficial in the trial.
This information must also be disclosed to
participants during the informed consent
process.” This duty is ascribed to multiple
stakeholders and the more general language
of benefit sharing from the 2008 version
has been replaced with specific emphasis on
participants who need access to study inter-
ventions.
On the reading I have been proposing,
this provision fits into a larger view of the
proper division of labor between research
and medical and public health systems. The
social function of research is to generate the
evidence necessary to improve the standard
of care and prevention and it falls to medi-
cal and public health systems to provide ac-
cess to this improved care on a large-scale
basis. When research is contemplated in
places where this division of labor may not
191
Declaration of Helsinki
take place, requiring strong assurance that
research is relevant to health needs or pri-
orities of the less-advantaged increases the
likelihood that information and interven-
tions will later be integrated into the health
systems that serve those populations. How-
ever, the time horizon for the process of
integrating new findings or interventions
into health systems can be protracted. The
requirement in paragraph 34 ensures that
there is some meaningful continuity in the
care that is provided to participants whose
health depends on access to study interven-
tions until the responsibility for providing
access to an improved standard of care can
be effectively discharged within the regular
health system.
Critics may counter that even if these con-
ditions are met, there is no guarantee that
host communities will receive a fair level
of benefit from hosting research. After all,
most studies do not vindicate successful
interventions. Three brief points about this
objection are worth considering. First, it
is not at all clear what a fair level of ben-
efit is for hosting a research study and the
most prominent accounts of this matter
are underdeveloped, at best, and internally
inconsistent at worst [11]. Second, rigor-
ously designed and well-executed trials that
produce negative findings do contribute
to the evidence base necessary to improve
the standard of care – if they are published.
Granted, this is not an immediate benefit
to communities. But compliance with the
requirements discussed above increases
the prospect that host communities will
have access to the long-term benefits that
come from increased understanding and the
eventual development of interventions that
can bridge health gaps.
Third, there is a genuine concern that stud-
ies might be carried out in ways that divert
local resources from other health priorities,
consume scarce resources, or otherwise bur-
den members of communities that already
suffer from problems rooted in poverty and
deprivation. These are legitimate concerns
and it would strengthen the DoH if it con-
tained a statement to the effect that research
conducted in resource scarce environments
must mitigate the prospect of these delete-
rious effects and should make positive con-
tributions to strengthen the capacity of local
health systems.
Reasonable Risk
In the previous section I suggested that
standard research ethics requirements re-
garding informed consent and the reason-
ableness of risk can be seen as helping to
provide public assurance to potential par-
ticipants that their moral status and their
interests will be respected in the course of
research participation. The 2013 revision of
the DoH includes a new provision in para-
graph 17 that adds to this assurance,namely,
that “Measures to minimise the risks must
be implemented.The risks must be continu-
ously monitored, assessed and documented
by the researcher.” However, other revisions
are somewhat puzzling.
The 2013 DoH retains language from the
2008 version to the effect that physicians
must not be involved in research unless
they are confident that the risks have been
“adequately assessed and can be properly
managed.” The 2008 version then states
that, “Physicians must immediately stop
a study when the risks are found to out-
weigh the potential benefits or when there
is conclusive proof of positive and benefi-
cial results” (par. 20, 2008). The claim that
studies must be stopped when findings
of benefit or lack thereof are conclusive
seems to follow directly from the scien-
tific purpose of research and from concern
for the welfare of study participants. Once
there is conclusive proof that risks of an
intervention outweigh its benefits, or its
beneficial effects have been confirmed,
the study question has been answered and
there is no longer a social purpose that
justifies exposing participants to study-
related risks.
The language form the 2008 version may
strike readers as too simplistic since, for
example, it may be difficult in practice to
know when the results of a single study
represent “conclusive proof.” The new ver-
sion retains this language, however, and
reads, “When the risks are found to out-
weigh the potential benefits or when there
is conclusive proof of definitive outcomes,
physicians must assess whether to contin-
ue, modify or immediately stop the study”
(par. 18, 2013). If the risks of participation
are found to outweigh potential benefits
or there is conclusive proof of definitive
outcomes, on what basis would a trial be
continued? Where the 2008 version states
a condition for stopping studies based on
confirmation of risks and benefits, the pro-
posed revision opens the possibility that
studies could continue after these issues
have been conclusively established with-
out providing substantive guidance about
how clinicians should make such decisions.
Moreover, continuing a study once “risks
are fond to outweigh the potential ben-
efits”seems to undermine any public assur-
ance to participants that their interests will
not be knowingly compromised through
study participation.
To avoid inconsistency, either the old lan-
guage should have been retained or the new
language should have been be clarified. For
example, it might be revised to say that as
evidence mounts to indicate that poten-
tial benefits do not outweigh risks or that
confirms beneficial results, physicians must
assess whether to continue, modify or im-
mediately stop the study.
Conclusion
I have tried to provide a reading of the
2013 DoH that integrates some of its key
provisions within a coherent, general view
of the research enterprise and the central
ethical challenges that it has to address.
Although this analysis draws heavily on
normative foundations not explicitly stated
192
Declaration of Helsinki
in the DoH, it is clear that those concerns
are not alien to the document. This analysis
highlights ways in which many proposed
changes increase the coherence and com-
prehensives of the document while indicat-
ing particular areas where difficulties and
inconsistencies remain. Because the DoH is
not explicit about these foundational issues,
however,it is vulnerable to appearing incon-
sistent, unfounded, or arbitrary to readers
who approach it with different interpretive
starting points.
References
1. London AJ. 2012. A Non-Paternalistic Model
of Research Ethics and Oversight: Assessing the
Benefits of Prospective Review. Journal of Law,
Medicine, and Ethics 40(4):930-944.
2. U.S. Department of Health and Human Ser-
vices, Fed. Regist. 76, 44512 (2011).
3. Federman DD, Hanna KE, Rodriguez LL, eds,
Responsible Research: A Systems Approach to Pro-
tecting Research Participants. (National Academ-
ics Press, Washington, DC, 2002).
4. A. J. London, J. Kimmelman, M. E. Emborg,
Research ethics. Beyond access vs. protection
in trials of innovative therapies. Science 328, 829
(May 14, 2010).
5. J. Hasford, T. Lamprecht, . Company observa-
tional post-marketing studies: drug risk assess-
ment and drug research in special populations-
-a study-based analysis. Eur J Clin Pharmacol
53, 369 (Jan, 1998).
6. London AJ, Kimmelman J, Carlisle B. 2012.
Rethinking Research Ethics: The Case of Post-
marketing Trials. Science 336 (May 4):544-545.
7. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis
JA. Bias in Associations of Emerging Biomark-
ers With Cardiovascular Disease. JAMA Intern
Med. 2013;173(8):664-671. doi:10.1001/ja-
mainternmed.2013.3018.
8. Nissen SE. Biomarkers in Cardiovascular Medi-
cine: The Shame of Publication Bias Comment
on “Bias in Associations of Emerging Biomark-
ers With Cardiovascular Disease”. JAMA In-
tern Med. 2013;173(8):671-672. doi:10.1001/
jamainternmed.2013.4074.
9. Rebecca Wolitz, Ezekiel Emanuel, Seema Shah.
2009. Rethinking the responsiveness require-
ment for international research. Lancet 374:
847–49
10. Jeffrey P. Kahn, Anna C. Mastroianni, and Jer-
emy Sugarman eds. Beyond Consent: Seeking
Justice in Research New York: Oxford Univer-
sity Press, 1998.
11. London AJ, Zollman KJS. 2010. Research at
the Auction Block: Some Problems for the Fair
Benefits Approach to International Research.
The Hastings Center Report 40(4):34-45.
Interest Disclosure: I was an invited speaker at
three WMA consultations regarding proposed
revisions to the Declaration of Helsinki.
Acknowledgement: I thank Jonathan Kimmel-
man and Danielle Wenner for their feedback on
a draft of this manuscript.
Alex John London, PhD
Professor of Philosophy and Director,
Center for Ethics and Policy,
Carnegie Mellon University.
5000 Forbes Avenue
Pittsburgh,
E-mail: ajlondon@andrew.cmu.edu
Since the 2000s, international ethical guide-
lines for human subjects research increas-
ingly emphasize that exclusion from research
participation must be justified. Despite
increased use of inclusive selection require-
ments for the choice of study populations, it
has so far not been evaluated what the moral
strength of these requirements is and who
should ensure that study populations are in-
clusively selected.
Methods
We analysed inclusive selection require-
ments or statements on justifying the exclu-
sion of study populations in ethical guide-
lines on human subjects research.
Results
We found that most ethical guidelines fo-
cus on inclusive selection requirements
From Justifying Inclusion to Justifying Exclusion of Study
Populations: Strengths and Limitations
Rieke van der Graaf Rolf HH Groenwold Shona Kalkman Diederick E Grobbee Johannes JM van Delden
193
Declaration of Helsinki
for reasons of justice, in particular correc-
tive justice for underrepresented groups in
research. A few guidelines mention scien-
tific reasons. We found that scientific rea-
sons may outweigh the concern for justice
as fair inclusion in some cases. In order to
yield generalizable health knowledge it may
sometimes be necessary to set up different
trials, or to deliberately exclude subgroups.
Moreover, if it is unknown whether inter-
vention effects differ between subgroups,
the inclusion of these subgroups should be
substantial and proportional. We also found
that most guidelines leave out who should
be responsible.
Conclusions
Some ethical guidelines seem to have gone
from the one extreme into the other: from
justifying inclusion to justifying exclusion.
However, a sole focus on corrective justice
does not necessarily render the choice of
study populations more ethically acceptable.
Furthermore, guidelines should consider
whose responsibility it is and determine
reasonable actions for those responsible to
ensure inclusive selection.
Since the 2000s, international ethical
guidelines for human subjects research in-
creasingly emphasize that exclusion from
research participation must be justified.
For instance, the International Guide-
lines for Biomedical Research Involv-
ing Human Subjects of the Council for
International Organizations for Medical
Sciences (CIOMS) state that “the exclu-
sion of groups or communities that might
benefit from study participation must be
justified” [1]. Likewise, the Canadian Tri
Council Policy Statement (TCPS) states that
“researchers should be inclusive in select-
ing participants” and have a duty “not to
exclude individuals or groups from par-
ticipation for reasons that are unrelated to
the research” [2]. The World Medical As-
sociation (WMA) has a similar paragraph
in its Declaration of Helsinki. Although
the WMA has never strongly required of
researchers to justify exclusion of popula-
tions that might benefit, nor to be inclusive
in their selection of study populations, it
has acknowledged that “populations that
are underrepresented in research should be
provided appropriate access to participa-
tion in research” in the 2008 version of the
Declaration [3].
Incorporation of requirements on inclu-
sive selection of study participants in ethi-
cal guidance documents may be explained
from an altered way of thinking about fair
inclusion of research participants during
the 80s and 90s. Until then, ethical guide-
lines on human subjects research focused
on justifying the use and inclusion of hu-
man beings solely for research purposes.
For instance the Belmont Report empha-
sizes that populations cannot be chosen
for study purposes only because they are
readily available [4]. But in the past three
decades research participation became to
be considered as a good that is not only
burdensome but also potentially beneficial
and hence should be distributed equally
[5]. Therefore, current thinking on fair in-
clusion not only implies that inclusion of
study populations has to be justified but
also their exclusion.
Although there may be an historical expla-
nation for incorporation of the idea of in-
clusive selection in ethical guidelines, sever-
al issues are unclear. First, what is the moral
strength of this requirement and what are
its limitations? Second, who is responsible
for fulfilling this requirement? These ques-
tions will be studied in this paper.Therefore,
we will analyze paragraphs on inclusive se-
lection in main international ethical guide-
lines on human subjects research and study
the rationales that underlie the inclusive se-
lection claims. Accordingly, we will evaluate
these rationales. We will also study which
actors are mentioned in the guidelines. Fur-
thermore,we will provide recommendations
for future use of inclusive selection require-
ments in international requirements.
Justice
In the last decades, main ethical guidance
documents have grounded the idea of jus-
tification of exclusion of subgroups in both
formal and material notions of justice (see
table).
According to formal justice, people are in
principle to be regarded as equal and hence
have to be treated equally. For instance, the
Canadian TCPS claims that “researchers
shall not exclude individuals from the op-
portunity to participate in research on the
basis of attributes such as culture, language,
religion, race, disability, sexual orientation,
ethnicity, linguistic proficiency, gender or
age” [2].
Inclusive selection requirements in ethical
guidance documents are also incorporated
in guidance documents on of corrective jus-
tice. In the introduction we mentioned that
the WMA emphasizes appropriate access
for underrepresented groups [3]. Likewise,
the CIOMS guidelines set out that: “as a
consequence of exclusions [in the past], in-
formation about diagnosis, prevention and
treatment of diseases in [these] groups of
persons is limited. This has resulted in a se-
rious class injustice”[1].Thus, in these para-
graphs justifying exclusion is a means to re-
store differences between trial populations.
Scientific reasons
Scientific reasons for selective inclusion
or exclusion follow from the need, or lack
thereof,to study effect modification by pop-
ulation characteristics of the benefits or risks
of interventions [6]. For instance, the NIH
guideline on The Inclusion of Women and Mi-
norities as Subjects in Clinical Research is a
proponent of inclusive selection of women
and minorities for certain types of studies
to be able to perform valid analyses [7].This
rationale for inclusive selection is unique
and not present in the other guidelines.Fur-
thermore, few guidelines that present more
194
Declaration of Helsinki
Table. Ethical guidance documents on inclusive selection of study populations
Content Rationale: Justice
CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects (2002), guideline 12
“Groups or communities to be invited to be
subjects of research should be selected in
such a way that the burdens and benefits of
the research will be equitably distributed.
The exclusion of groups or communities that
might benefit from study participation must
be justified.”
“Equity requires that no group or class of persons should bear more than its fair share of the
burdens of participation in research. Similarly, no group should be deprived of its fair share of
the benefits of research, short-term or long-term.”
“Subjects should be drawn from the qualifying population in the general geographic area of
the trial without regard to race, ethnicity, economic status or gender unless there is sound
scientific reason to do otherwise.”
“In the past, groups of persons were excluded form participation in research for what were then
considered good reasons. As a consequence of such exclusions, information about the diagnosis,
prevention and treatment of diseases in such groups is limited.This has resulted in a serious
class injustice.”
WMA, Declaration of Helsinki (2008), paragraph 5
“Populations that are underrepresented
in medical research should be provided
appropriate access to participation in
research.”
“Appropriate access”
Canadian Tri-Council Policy Statement 2: Ethical Conduct for Research Involving Humans (2010), chapter 4
“Taking into account the scope and
objectives of their research, researchers
should be inclusive in selecting participants.
Researchers shall not exclude individuals
from the opportunity to participate in
research on the basis of attributes such as
culture, language, religion, race, disability,
sexual orientation, ethnicity, linguistic
proficiency, gender or age, unless there is a
valid reason for the exclusion.”
“Appropriate inclusion” is “based on the principle of justice”, meaning that “researchers shall
not exclude individuals from the opportunity to participate in research on the basis of attributes
such as culture, language, religion, race, disability, sexual orientation, ethnicity, linguistic
proficiency, gender or age, unless there is a valid reason for exclusion”.
“Not to exclude individuals or groups from participation for reasons that are unrelated to the
research” (..) “is explicitly stated because groups have been inappropriately excluded from
participation in research on the basis of attributes such as gender, race, ethnicity, age and
disability”.
“[Inappropriate] exclusion of women [in the past], where unwarranted, has delayed the
advancement of knowledge, denied potential benefits to women, and exposed women to
harm when research findings from male-only research projects were generalized inappropriately
to women”.
“As is the case with women, the inclusion of children in research advances commitment to
justice in research by improving our knowledge of, and ability to respond to, the unique needs
of children throughout their development.”
UNAIDS Ethical Considerations in Biomedical HIV Prevention Trials (2007), guidance point 7, 9 and 10
“Individuals should not be excluded from the
opportunity to participate without a good
scientific reason or a susceptibility to risk
that justifies their exclusion.”
“In order to conduct biomedical HIV prevention trials in an ethically acceptable manner, (…)
the selection of participating communities and individuals must be fair and justified in terms of
the scientific goals of the research. “
“Women, including pregnant women, potentially pregnant women and breast-feeding women,
should be eligible for enrolment in HIV preventive vaccine trials, both as a matter of equity
and because in many communities throughout the world women are at high risk of HIV
prevention.”
“Children, including infants and adolescents, should be eligible for enrolment in HIV
preventive vaccine trials, both as a matter of equity and because in many communities
throughout the world children are at high risk of HIV infection.”
195
Declaration of Helsinki
justice-oriented reasons for having to justify
exclusion of study populations acknowledge
scientific limitations for excluding certain
populations. The UNAIDS/WHO guide-
line on Ethical Considerations in Biomedical
HIV Prevention Trials emphasizes that in-
clusion of study populations must not only
be fair but also “justified in terms of the sci-
entific goals of the research” [8]. The NIH
guideline also point at scientific limitations
of inclusive selection.
It distinguishes three situations in the selec-
tion of study populations: 1) prior studies
support the existence of significant differ-
ences in intervention effect between groups
of subjects; 2) prior studies support no sig-
nificant differences in intervention effect;
and 3) prior studies neither support nor
negate significant differences in interven-
tion effect. Regarding the first situation the
guideline states that “… if men and women
are thought to respond differently to an in-
tervention, then the Phase III clinical trial
must be designed to answer two separate
primary questions, one for men and the
other for women… ”. The opposite situa-
tion (situation 2) occurs when there is no
evidence for a differential intervention ef-
fect: “If the data from prior studies strongly
support no significant differences in inter-
vention effect based on sex, then gender
will not be required as subject selection
criteria. However, the inclusion and analysis
of gender subgroups is still strongly encour-
aged.” The third situation is most common
in practice. “If the data from prior studies
neither strongly support nor strongly negate
the existence of significant differences in in-
tervention effect based on gender subpopu-
lation comparisons, then the NIH-defined
Phase III clinical trial will be required to
include sufficient and appropriate entry
of gender participants, so that valid analy-
sis of the intervention effects can be per-
formed” [7].
Actors
Most guidelines are silent on the responsi-
ble person for inclusive selection.The Cana-
dian TCPS [2] bestows researchers with this
obligation, and the NIH has determined
that its Director shall ensure inclusive se-
lection [7].
Discussion
In this paper we studied two issues: 1. the
moral strength of the inclusive selection
requirement and 2. who should be respon-
sible for inclusive selection. As regards the
first issue, we have seen that inclusive selec-
tion requirements have their basis in prin-
ciples of justice which determine the moral
strength of these claims. Justice as equity
and as corrective justice is put forward with
regard to the selection of study populations.
The function of equity is to assure that peo-
ple are not excluded for arbitrary reasons
when they meet the inclusion criteria. Cor-
rective justice has a different function. It as-
sures that groups that have been underrep-
resented in research are not systematically
excluded as a class.
Increased attention for inclusion of under-
represented groups is to a certain extent
essential since it may render interventions
for these groups more evidence-based. For
instance, pharmacokinetics and pharmaco-
dynamics of drugs during pregnancy have
been poorly studied, which may adversely
impact the health of both pregnant women
and their fetuses [9].
However, fair inclusion of underrepresent-
ed study groups should not be considered
as being as inclusive as possible, as some
guidelines seem to suggest. There are scien-
tific limitations to justice-based reasons for
justifying exclusion. We have seen that the
NIH does not always promote the inclusion
of women and minorities and sets out that
from a scientific perspective three situations
should be distinguished.
In the following, we will discuss these three
situations indicated by the NIH guideline.
We focus on inclusion and exclusion of men
and women, though these gender groups
could be substituted for other subgroups
(mutatis mutandis).
Situation 1
From a scientific perspective, the NIH
guideline seems obvious. The overall ob-
served intervention effect in a population of
Content Rationale: Justice
NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research (2001)
“It is the policy of NIH that women and
members of minority groups and their
subpopulations must be included in all
NIH-funded clinical research, unless a clear
and compelling rationale and justification
establishes (…) that inclusion is inappropriate
with respect to the health of the subjects or
the purpose of the research.”
“Since a primary aim of research is to provide scientific evidence leading to a change in health
policy or standard of care, it is imperative to determine whether the intervention or therapy
being studied affects women or men or members of minority groups and their subpopulations
differently.”
196
Declaration of Helsinki
men and women is a (weighted) average of
the effect among men and the effect among
women. If the intervention effect differs
between men and women, the overall effect
neither applies to men,nor to women; it will
only apply to a population with a similar dis-
tribution of men and women as in the trial.
Randomized trials are typically designed to
provide evidence on the overall effective-
ness of treatment in the trial population.
To identify differential intervention effects
requires much more study participants.10
Hence, in case of strong prior evidence of a
differential intervention effect conducting a
trial in a population that is a mixture of sub-
groups is unreasonable, because it provides
an estimate of the intervention effect that is
little informative and the study is probably
too small to demonstrate differential inter-
vention effects. From an ethical perspective,
it is essential that guidelines that focus pri-
marily on justification of exclusion for rea-
sons of justice acknowledge that in case of
differential intervention effects, it is scien-
tifically preferable to set up different trials
instead of being as inclusive as possible in
a single trial. The value of knowledge gen-
erated from a study with a heterogeneous
study population may then be limited com-
pared to multiple studies each conducted in
homogenous populations.
Situation 2
Also when strong prior evidence against
differential intervention effects, the NIH
guideline seems rational. In such situations,
a trial can be conducted in either men only,
women only, or any combination of the two
groups. Actually, results from trials in which
not a single woman was included can still
be generalized to women as long as the as-
sumption of no differential intervention ef-
fects holds.For example,even if trials on the
effect of antibiotics in children with acute
otitis media are conducted in boys only, one
will probably assume antibiotics are equally
effective in girls, because the mechanism
through which the intervention acts is the
same for boys and girls [11]. Thus, in the
absence of differential intervention effects,
the exclusion of any such subgroup will not
affect generalizability.
From both a scientific and ethical perspec-
tive, it may even be sensible to deliberately
exclude particular subgroups. For example,
in a trial on the prevention of cardiovascular
disease the exclusion of women will likely
decrease sample size requirements or dura-
tion of the trial, since women have a lower
risk of cardiovascular morbidity than men.
Hence, in case of equal intervention effects
among men and women, including only
men in a trial would require less study par-
ticipants compared to a trial including both
men and women and thus reduce the bur-
den for study participants, without hamper-
ing generalizability of results.Therefore, the
disclaimer in the NIH guideline in situation
2 (i.e., to include gender subgroups even if
prior studies have shown no difference be-
tween these subgroups) is remarkable. The
ethical value of this disclaimer is question-
able since it may increase the required sam-
ple size, as indicated above, and hence may
extra burden participants as a group. There-
fore, the rationale for this disclaimer needs
to be explained.
Situation 3
If it is unknown whether the intervention
effect differs between men and women, as
will often be the case, the NIH guideline
indicates that both men and women should
be included. However the phrase “sufficient
and appropriate” inclusion of participants
from both genders in the guideline is un-
clear. If it turns out that the intervention
effect differs between men and women, the
observed effect is a (weighted) average of
the effect among men and the effect among
women. In that case, it could be invalid to
generalize findings from a study in which
say only three out of a thousand study par-
ticipants were women to a population of
whom 40% are women. Hence, if the possi-
bility of a differential intervention effect by
gender cannot be excluded, the proportion
of women enrolled in a trial should be simi-
lar to the proportion of women among typi-
cal users. If a random subset of those typi-
cal users (e.g., subjects with hypertension,
who constitute the typical antihypertensive
drug users) is included in a trial, inclusion
is proportional and results will generalize
to populations with a similar proportion of
women. However, physician treat individu-
als rather than groups and they may thus
require more evidence regarding specific
subgroups. For example, if 1% of the typi-
cal users is female, one may nevertheless re-
quire e.g. 10% inclusion of women in a trial
in order to generalize results from that trial
to an individual female patient. In other
words, fair inclusion means that in those
cases where it is unknown whether the in-
tervention effect differs between men and
women, researchers should clarify whether
participation of subgroups is either propor-
tional or substantial.
We note that a trial on the efficacy of an in-
tervention is typically designed to detect an
overall intervention effect and will not pro-
vide evidence of the presence (or absence) of
differential effects [10].This is acknowledged
in the NIH guideline, which states that “the
trial will not be required to provide high sta-
tistical power for these comparisons”. The
analysis to assess whether the intervention
effect differs between subgroups seems to be
(only) secondary and often impossible.
If the question is not what the overall inter-
vention effect is, but whether the interven-
tion effect differs between men and women,
one would typically design a study in which
the ratio between men and women is not
proportional to that ratio among future us-
ers. In fact, a design with equal numbers of
men and women may be more efficient to
detect a differential intervention effect. We
note that such a trial is designed to answer
a different research question (namely that
of differences in the intervention effect be-
tween men and women) than the trial that
197
Declaration of Helsinki
is aimed to show an overall intervention ef-
fect, on which the NIH guideline focuses.
In summary, although the NIH guideline
on women and minorities demonstrates that
scientific considerations are essential for fair
inclusion, the guideline should be further
sharpened. If there are no differential inter-
vention effects it remains unclear why the
guideline suggests inclusion of both gender
groups. Furthermore, when it is unknown
whether the intervention effect differs be-
tween men and women the inclusion should
either be proportional or substantial.
The second question was who should be
responsible for inclusive selection. Most
guidelines are very brief at this point. The
Canadian TCPS sets out that the obligation
falls on the shoulders of the researcher. It is
however questionable whether the research-
er should be solely responsible now we have
seen that corrective justices underlies in-
clusive selection claims. Although the re-
searcher is directly involved in the inclusion
process, there should also be an authority or
(inter)national organization which is in the
position to ensure that a given study popula-
tion has appropriate access to participation.
In theory, there will also be a moment that
inclusive selection requirements for reasons
of corrective justice are no longer needed.
If researchers are imposed with this obliga-
tion, they should have access to information
on fair inclusion of study populations on
a global level. Currently, empirical data on
equitable distribution of burdens and ben-
efits among trial populations is lacking.
Conclusions and
recommendations
Many ethical guidelines on human subjects
research emphasize inclusive selection of
study populations in order to prevent arbi-
trary exclusion or to prioritize groups that
have been underrepresented in research.
However, in order to yield generalizable
knowledge it may sometimes be necessary
to set up different trials, or to deliberately
exclude subgroups. Moreover, if it is un-
known whether intervention effects differ
between subgroups, the inclusion of these
subgroups should be either proportional or
substantial. We caution that a sole focus on
justice as equity and corrective justice does
not necessarily render the choice of study
populations more ethically acceptable.
Furthermore, we emphasize that guidelines
should clarify who is responsible for inclu-
sive selection and what actions are required
of this person or organization. The Decla-
ration of Helsinki and the CIOMS guidelines
are unclear at this point. In the (next) revi-
sion process the guideline makers may want
to consider whether and how the actors of
this obligation may be able to fulfil the idea
that exclusion of study populations must be
justified.
References
1. Council for International Organizations of
Medical Sciences. International Ethical Guide-
lines for Biomedical Research Involving Human
Subjects. Geneva, Switzerland: CIOMS; 2002.
2. Canadian Institutes of Health Research, Natu-
ral Sciences and Engineering Research Coun-
cil of Canada, Social Sciences and Humanities
Research Council Canada. Tri-Council Policy
Statement. Ethical conduct for research involving
humans, December 2010.
3. World Medical Association. Declaration of Hel-
sinki: Ethical Principles for Medical Research In-
volving Human Subjects. Seoul: 2008.
4. Office of the Secretary. Ethical Principles and
Guidelines for the Protection of Human Sub-
jects of Research. The National Commission for
the Protection of Human Subject of Biomedical
and Behavioral Research. The Belmont Report.
April 18, 1979
5. Emanuel E, Grady C. Four paradigms of clinical
research and research oversight. Camb Q Healthc
Ethic 2006;16:82-96.
6. Grobbee DE, Hoes AW. Clinical epidemiology.
Boston: Jones and Bartlett 2009, pp 38.
7. National Institutes of Health, NIH Policy and
Guidelines on The Inclusion of Women and Minori-
ties as Subjects in Clinical Research – Amended,
October, 2001.
8. UNAIDS/WHO. Ethical considerations in
biomedical HIV prevention trials. Geneva,
2007/2012.
9. Haas DM, Gallauresi B, Shields K, Zeitlin D,
Clark SM, Hebert MF, et al. Pharmacotherapy
and Pregnancy: Highlights from the Third
International Conference for Individualized
Pharmacotherapy in Pregnancy. Clin Transl Sci
2011;4:204-9.
10. Brookes ST, Whitely E, Egger M, Smith GD,
Mulheran PA, Peters TH. Subgroup analyses
in randomized trials: risks of subgroup-specific
analyses; power and sample size for the interac-
tion test. J Clin Epidemiol 2004;57:229-236.
11. Rovers MM, Glasziou P, Appelman CL, Burke
P, McCormick DP, Damoiseaux RA, Gaboury
I, Little P, Hoes AW, Antibiotics for acute otitis
media: a meta-analysis with individual patient
data. Lancet 2006;368:1429-1435.
Rieke van der Graaf,
University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care
E-mail: r.vandergraaf@umcutrecht.nl
Rolf HH Groenwold,
University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care
Shona Kalkman,
University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care
Diederick E Grobbee,
University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care,
University Professor International
Health Sciences and Global Health
Johannes JM van Delden
University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care
Utrecht, Netherlands
Johannes JM van Delden and Rieke van der
Graaf are members of the Working Group
of the Revision of the CIOMS guidelines.
The ideas on improvement of the respon-
siveness requirement in the CIOMS guide-
lines are the authors’ own and do not reflect
the position of CIOMS.
198
Declaration of Helsinki
Increased protection for people taking part
in medical research has been proposed by
the World Medical Association in changes
to its Declaration of Helsinki.
After a revision process lasting two years,
the WMA today adopted and published a
revised version of the Declaration on medi-
cal research, which next year celebrates its
50th
anniversary.
Delegates at the WMA’s annual Assembly
in Fortaleza, Brazil, voted overwhelmingly
to support changes to the Declaration,which
not only provide for increased protection for
vulnerable groups involved in research, but
also include a new provision for compensat-
ing people harmed as a result of participating
in research. In addition there are expanded
requirements for post-study arrangements to
ensure that participants involved in research
are informed of the results and have access to
any beneficial treatments that emerge.
Dr. Margaret Mungherera, President of the
WMA, said: ‘The changes agreed today are
all about providing a greater degree of pro-
tection for those involved in research. We
have spent two years consulting our na-
tional medical association members, outside
experts and the public and we are satisfied
that today we have a Declaration that re-
quires greater transparency about medical
research, greater accountability and in-
creased patient safety.
‘The changes also place more obligations on
the sponsors of research, on the research-
ers themselves and on host governments to
protect research subjects.’
This is the seventh time the Declaration of
Helsinki has been revised since its incep-
tion, with notes of clarification being added
in 2002 and 2004. It is one of the most
important international ethical regulations
in biomedical research and is a core docu-
ment of the WMA. It was adopted by the
18th
General Assembly of the WMA in
Helsinki, Finland in 1964 and consists of
a collection of ethical principles which set
out clear and easily readable guidelines for
medical research involving human subjects.
Themes and Soundbites
Facts
• Next year (2014) is the 50th
anniversary of
the Declaration
• The Declaration has been revised six
times with two notes of clarification
• Previous revisions in 1975, 1983, 1989,
1996, 2000 and 2008
• Sixth version was adopted in Edinburgh
in 2000.The process lasted three years
• In 2002 there was a note of clarification
• The original version was adopted in 1964
after a 12-year debate
• Originally the Declaration comprised 11
articles and 713 words
• The most recent revision was completed
in 2008
• It was the first significant effort of the
medical community to regulate research
itself, and forms the basis of most subse-
quent documents
• The Declaration is incorporated into
many laws and regulations
Phrases
• WMA came into being because of the
lack of research ethics
• Declaration grew out of the horrific re-
search during WWII carried out by phy-
sicians
• Prominent status
• Unique standing of Declaration
• One of the most important international
ethical documents
• It is the cornerstone of contemporary re-
search ethics
• Public trust
• Doctors acting in patients’ best interests
• The duty of physicians to safeguard the
health of patients
• Recognised internationally as the stan-
dard guidance on medical research ethics
• Medical progress is dependent on re-
search on human subjects
• Advances in medicines used today to save
lives and relieve suffering would not be
possible without research involving hu-
man subjects
• Millions of people have benefited from
research carried out under DoH guide-
lines
• The Declaration must be responsive to
the fast changing world of medicine
• Declaration lays out the roadmap for
trust and ethics
• Medical research is about understanding
the causes, development and effects of
diseases and improving preventive, diag-
nostic and therapeutic interventions
• One of the principles of the DoH is that
medical research involving the vulnerable
or disadvantaged population can only be
justified if the research is responsive to
the health needs and priorities of this
community and if there is a reasonable
likelihood that this population or com-
munity stands to benefit from the results
of the research
Revision Process
• Latest workgroup was formed in 2011
• Four expert conferences have been held
• The core principles remain unchanged
• Increased protection for vulnerable
groups
• More protection for participants
• DOH requires that research only be con-
ducted if the importance of the objective
outweighs the inherent risks and burdens
to the research subjects
• New provision for compensation
• Expanded requirements for post study ar-
rangements
• A more systematic approach to use of
placebos
• Improved readability
• Clarification of the role of research ethics
committees
• The April-June public consultation re-
sulted in 129 submissions
WMA Publishes its Revised Declaration
of Helsinki
199
Declaration of Helsinki
WMA Declaration of Helsinki –
Ethical Principles for Medical
Research Involving Human
Subjects
Adopted by the 18th
WMA General Assembly, Helsinki, Finland, June
1964 and amended by the: 29th
WMA General Assembly, Tokyo, Ja-
pan, October 1975 35th
WMA General Assembly, Venice, Italy, October
1983 41st
WMA General Assembly, Hong Kong, September 1989 48th
WMA General Assembly, Somerset West, Republic of South Africa, Oc-
tober 1996 52nd
WMA General Assembly, Edinburgh, Scotland, Octo-
ber 2000 53rd
WMA General Assembly, Washington DC, USA, October
2002 (Note of Clarification added) 55th
WMA General Assembly,Tokyo,
Japan, October 2004 (Note of Clarification added) 59th
WMA General
Assembly, Seoul, Republic of Korea, October 2008 64th
WMA General
Assembly, Fortaleza, Brazil, October 2013
Preamble
1. The World Medical Association (WMA) has developed the Dec-
laration of Helsinki as a statement of ethical principles for medical
research involving human subjects, including research on identifi-
able human material and data.
The Declaration is intended to be read as a whole and each of its
constituent paragraphs should be applied with consideration of all
other relevant paragraphs.
2. Consistent with the mandate of the WMA, the Declaration is
addressed primarily to physicians. The WMA encourages others
who are involved in medical research involving human subjects to
adopt these principles. 
General Principles
3. The Declaration of Geneva of the WMA binds the physician
with the words,“The health of my patient will be my first consider-
ation,” and the International Code of Medical Ethics declares that,
“A physician shall act in the patient’s best interest when providing
medical care.”
4. It is the duty of the physician to promote and safeguard the
health, well-being and rights of patients, including those who are
involved in medical research. The physician’s knowledge and con-
science are dedicated to the fulfilment of this duty.
5. Medical progress is based on research that ultimately must in-
clude studies involving human subjects.
6. The primary purpose of medical research involving human sub-
jects is to understand the causes,development and effects of diseases
and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best proven inter-
ventions must be evaluated continually through research for their
safety, effectiveness, efficiency, accessibility and quality.
7. Medical research is subject to ethical standards that promote and en-
sure respect for all human subjects and protect their health and rights.
8. While the primary purpose of medical research is to generate
new knowledge, this goal can never take precedence over the rights
and interests of individual research subjects.
9. It is the duty of physicians who are involved in medical research
to protect the life, health, dignity, integrity, right to self-determina-
tion, privacy, and confidentiality of personal information of research
subjects. The responsibility for the protection of research subjects
must always rest with the physician or other health care profes-
sionals and never with the research subjects, even though they have
given consent.
10. Physicians must consider the ethical, legal and regulatory norms
and standards for research involving human subjects in their own
countries as well as applicable international norms and standards.
No national or international ethical, legal or regulatory requirement
should reduce or eliminate any of the protections for research sub-
jects set forth in this Declaration.
11. Medical research should be conducted in a manner that mini-
mises possible harm to the environment.
12. Medical research involving human subjects must be conducted
only by individuals with the appropriate ethics and scientific edu-
cation, training and qualifications. Research on patients or healthy
volunteers requires the supervision of a competent and appropri-
ately qualified physician or other health care professional.
13. Groups that are underrepresented in medical research should be
provided appropriate access to participation in research.
14. Physicians who combine medical research with medical care
should involve their patients in research only to the extent that this
is justified by its potential preventive,diagnostic or therapeutic value
and if the physician has good reason to believe that participation in
the research study will not adversely affect the health of the patients
who serve as research subjects.
200
Declaration of Helsinki
15. Appropriate compensation and treatment for subjects who are
harmed as a result of participating in research must be ensured.
Risks, Burdens and Benefits 
16. In medical practice and in medical research, most interventions
involve risks and burdens.
Medical research involving human subjects may only be conducted
if the importance of the objective outweighs the risks and burdens
to the research subjects.
17. All medical research involving human subjects must be pre-
ceded by careful assessment of predictable risks and burdens to the
individuals and groups involved in the research in comparison with
foreseeable benefits to them and to other individuals or groups af-
fected by the condition under investigation.
Measures to minimise the risks must be implemented. The risks
must be continuously monitored, assessed and documented by the
researcher. 
18. Physicians may not be involved in a research study involving
human subjects unless they are confident that the risks have been
adequately assessed and can be satisfactorily managed.
When the risks are found to outweigh the potential benefits or
when there is conclusive proof of definitive outcomes, physicians
must assess whether to continue, modify or immediately stop the
study.
Vulnerable Groups and Individuals
19. Some groups and individuals are particularly vulnerable and
may have an increased likelihood of being wronged or of incurring
additional harm.
All vulnerable groups and individuals should receive specifically
considered protection.
20. Medical research with a vulnerable group is only justified if the
research is responsive to the health needs or priorities of this group
and the research cannot be carried out in a non-vulnerable group.
In addition, this group should stand to benefit from the knowledge,
practices or interventions that result from the research.
Scientific Requirements and Research Protocols 
21. Medical research involving human subjects must conform to
generally accepted scientific principles, be based on a thorough
knowledge of the scientific literature, other relevant sources of
information, and adequate laboratory and, as appropriate, animal
experimentation. The welfare of animals used for research must be
respected.
22. The design and performance of each research study involving
human subjects must be clearly described and justified in a research
protocol.
The protocol should contain a statement of the ethical consider-
ations involved and should indicate how the principles in this Dec-
laration have been addressed.The protocol should include informa-
tion regarding funding, sponsors, institutional affiliations, potential
conflicts of interest, incentives for subjects and information regard-
ing provisions for treating and/or compensating subjects who are
harmed as a consequence of participation in the research study.
In clinical trials, the protocol must also describe appropriate ar-
rangements for post-trial provisions.
Research Ethics Committees
23. The research protocol must be submitted for consideration,
comment, guidance and approval to the concerned research ethics
committee before the study begins. This committee must be trans-
parent in its functioning, must be independent of the researcher,
the sponsor and any other undue influence and must be duly quali-
fied. It must take into consideration the laws and regulations of the
country or countries in which the research is to be performed as well
as applicable international norms and standards but these must not
be allowed to reduce or eliminate any of the protections for research
subjects set forth in this Declaration. 
The committee must have the right to monitor ongoing studies.The
researcher must provide monitoring information to the committee,
especially information about any serious adverse events. No amend-
ment to the protocol may be made without consideration and ap-
proval by the committee. After the end of the study, the researchers
must submit a final report to the committee containing a summary
of the study’s findings and conclusions. 
Privacy and Confidentiality 
24. Every precaution must be taken to protect the privacy of re-
search subjects and the confidentiality of their personal information.
Informed Consent 
25. Participation by individuals capable of giving informed consent
as subjects in medical research must be voluntary. Although it may
be appropriate to consult family members or community leaders, no
Declaration of Helsinki
individual capable of giving informed consent may be enrolled in a
research study unless he or she freely agrees.
26. In medical research involving human subjects capable of giv-
ing informed consent, each potential subject must be adequately
informed of the aims, methods, sources of funding, any possible
conflicts of interest, institutional affiliations of the researcher, the
anticipated benefits and potential risks of the study and the dis-
comfort it may entail, post-study provisions and any other rel-
evant aspects of the study.The potential subject must be informed
of the right to refuse to participate in the study or to withdraw
consent to participate at any time without reprisal. Special atten-
tion should be given to the specific information needs of indi-
vidual potential subjects as well as to the methods used to deliver
the information.
After ensuring that the potential subject has understood the infor-
mation, the physician or another appropriately qualified individual
must then seek the potential subject’s freely-given informed con-
sent, preferably in writing. If the consent cannot be expressed in
writing, the non-written consent must be formally documented and
witnessed.
All medical research subjects should be given the option of being
informed about the general outcome and results of the study.
27. When seeking informed consent for participation in a research
study the physician must be particularly cautious if the potential
subject is in a dependent relationship with the physician or may
consent under duress. In such situations the informed consent must
be sought by an appropriately qualified individual who is completely
independent of this relationship.
28. For a potential research subject who is incapable of giving in-
formed consent,the physician must seek informed consent from the
legally authorised representative. These individuals must not be in-
cluded in a research study that has no likelihood of benefit for them
unless it is intended to promote the health of the group represented
by the potential subject, the research cannot instead be performed
with persons capable of providing informed consent, and the re-
search entails only minimal risk and minimal burden.
29. When a potential research subject who is deemed incapable of
giving informed consent is able to give assent to decisions about
participation in research, the physician must seek that assent in ad-
dition to the consent of the legally authorised representative. The
potential subject’s dissent should be respected.
30. Research involving subjects who are physically or mentally inca-
pable of giving consent, for example, unconscious patients, may be
done only if the physical or mental condition that prevents giving
informed consent is a necessary characteristic of the research group.
In such circumstances the physician must seek informed consent
from the legally authorised representative. If no such representative
is available and if the research cannot be delayed,the study may pro-
ceed without informed consent provided that the specific reasons
for involving subjects with a condition that renders them unable to
give informed consent have been stated in the research protocol and
the study has been approved by a research ethics committee. Con-
sent to remain in the research must be obtained as soon as possible
from the subject or a legally authorised representative.
31. The physician must fully inform the patient which aspects of
their care are related to the research. The refusal of a patient to
participate in a study or the patient’s decision to withdraw from
the study must never adversely affect the patient-physician rela-
tionship.
32. For medical research using identifiable human material or data,
such as research on material or data contained in biobanks or simi-
lar repositories, physicians must seek informed consent for its col-
lection, storage and/or reuse. There may be exceptional situations
where consent would be impossible or impracticable to obtain for
such research.In such situations the research may be done only after
consideration and approval of a research ethics committee.
Use of Placebo
33. The benefits, risks, burdens and effectiveness of a new interven-
tion must be tested against those of the best proven intervention(s),
except in the following circumstances:
Where no proven intervention exists, the use of placebo, or no in-
tervention, is acceptable; or
Where for compelling and scientifically sound methodological rea-
sons the use of any intervention less effective than the best proven
one, the use of placebo, or no intervention is necessary to determine
the efficacy or safety of an intervention and the patients who receive
any intervention less effective than the best proven one, placebo, or
no intervention will not be subject to additional risks of serious or
irreversible harm as a result of not receiving the best proven inter-
vention. 
Extreme care must be taken to avoid abuse of this option.
Post-Trial Provisions
34. In advance of a clinical trial, sponsors, researchers and host
country governments should make provisions for post-trial access
for all participants who still need an intervention identified as ben-
eficial in the trial.This information must also be disclosed to partici-
pants during the informed consent process.
IV
Contents
Research Registration and Publication
and Dissemination of Results
35. Every research study involving human subjects must be reg-
istered in a publicly accessible database before recruitment of the
first subject.
36. Researchers, authors, sponsors, editors and publishers all have
ethical obligations with regard to the publication and dissemination
of the results of research. Researchers have a duty to make pub-
licly available the results of their research on human subjects and
are accountable for the completeness and accuracy of their reports.
All parties should adhere to accepted guidelines for ethical report-
ing. Negative and inconclusive as well as positive results must be
published or otherwise made publicly available. Sources of funding,
institutional affiliations and conflicts of interest must be declared
in the publication. Reports of research not in accordance with the
principles of this Declaration should not be accepted for publication.
Unproven Interventions in Clinical Practice
37. In the treatment of an individual patient, where proven inter-
ventions do not exist or other known interventions have been in-
effective, the physician, after seeking expert advice, with informed
consent from the patient or a legally authorised representative,
may use an unproven intervention if in the physician’s judgement
it offers hope of saving life, re-establishing health or alleviating
suffering. This intervention should subsequently be made the ob-
ject of research, designed to evaluate its safety and efficacy. In all
cases, new information must be recorded and, where appropriate,
made publicly available.
Disclaimer: © 2013 World Medical Association, Inc. All Rights Reserved. All intellectual property rights in the Declaration of Helsinki are vested
in the World Medical Association. Previous permissions granted to publish or reproduce otherwise WMA policy don’t apply to this version of the
Declaration of Helsinki until January 1st
, 2014. For further questions, please contact the WMA secretariat at secretariat@wma.net
Address of Past President of WMA Cecil B Wilson . . . . . 161
Inaugural Address of Dr. Margaret Mungherera . . . . . . . . 162
WMA President – Elect Dr. Xavier DEAU . . . . . . . . . . . . 164
64rd
WMA General Assembly and 195th
/196th
Council Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
WMA Statement on Natural Variations of Human
Sexuality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
WMA Resolution in Support of the Brazilian
Medical Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
WMA Resolution on the Prohibition of Chemical
Weapons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
WMA Resolution on Criminalisation of Medical Practice . . . 178
WMA Statement on the United Nations Resolution
for a Moratorium on the Use of the Death Penalty . . . . . . 179
WMA Statement on Fungal Disease Diagnosis
and Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
WMA Statement on Forensic Investigations
of the Missing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
WMA Council Resolution on Standardisation
in Medical Practice and Patient Safety . . . . . . . . . . . . . . . . 181
WMA Resolution on the Healthcare Situation in Syria . . 181
WMA Statement on the Right of Rehabilitation
of Victims of Torture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
WMA Statement on Human Papillomavirus Vaccination . . . 183
WMA Resolution on Women’s Rights to Health Care and
How That Relates to the Prevention of Mother-to-Child
HIV Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
If Perfect Isn’t Possible, Is The Good “Good Enough?”
Placebos,Post-Trial Provisions and the Politics of Helsinki . . . 185
Justification, Coherence and Consistency of Provisions
in the Revised Declaration of Helsinki . . . . . . . . . . . . . . . . 188
From Justifying Inclusion to Justifying Exclusion
of Study Populations: Strengths and Limitations . . . . . . . . 192
WMA Publishes its Revised Declaration of Helsinki . . . . . . 198
WMA Declaration of Helsinki – Ethical Principles
for Medical Research Involving Human Subjects . . . . . . . 199